<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 6 -->
<!-- Creation date: 2014-08-12T00:26:48Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:ttph="http://tphase.com/20140630" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="ttph-20140630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:GovernmentContractReceivable contextRef="eol_PE719251--1410-Q0005_STD_0_20111031_0_926233x1126999_926437x923140_926744x1070296" unitRef="iso4217_USD" decimals="-5" id="id_5950807_AD0A8FD9-8B8B-48BD-AD74-83FF74B0E077_2001_0">13300000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="eol_PE719251--1410-Q0005_STD_0_20111130_0_926233x1038577_926744x1070296" unitRef="iso4217_USD" decimals="0" id="id_5950807_026A8A24-5BD6-46F7-BD8C-FD156AFBEBF8_2001_0">980000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="eol_PE719251--1410-Q0005_STD_0_20120131_0_926233x1126999_926437x923140_926744x1112837" unitRef="iso4217_USD" decimals="-5" id="id_5950807_2730A159-51F0-43F5-BD69-D11F640F32CA_4001_1">39800000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="eol_PE719251--1410-Q0005_STD_0_20120131_0_926233x1126999_926744x1112837_928294x1262319" unitRef="iso4217_USD" decimals="-5" id="id_5950807_2730A159-51F0-43F5-BD69-D11F640F32CA_5001_2">22000000</us-gaap:GovernmentContractReceivable>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE719251--1410-Q0005_STD_0_20130228_0_926396x1061900" unitRef="pure" decimals="INF" id="id_5950807_0B861D5C-A061-4E68-A3D9-EA95BD44E5C7_4001_5">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE719251--1410-Q0005_STD_0_20130228_0_926396x1117504" unitRef="pure" decimals="INF" id="id_5950807_0B861D5C-A061-4E68-A3D9-EA95BD44E5C7_5001_4">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE719251--1410-Q0005_STD_0_20130228_0_926396x1117504_931308x1008215_932980x930400" unitRef="shares" decimals="INF" id="id_5950807_4EEC327D-1763-4C67-B92B-7829DBD0EB3D_7001_11">233372</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE719251--1410-Q0005_STD_0_20130228_0_926396x1117504_931308x1008215_932980x930400" unitRef="iso4217_USD_per_Right" decimals="INF" id="id_5950807_4EEC327D-1763-4C67-B92B-7829DBD0EB3D_7001_12">0.2571</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE719251--1410-Q0005_STD_0_20130228_0_929038x1056245" unitRef="shares" decimals="INF" id="id_5950807_EAABAE2B-E268-4B76-85A6-F608444BE228_3001_0">1688777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE719251--1410-Q0005_STD_0_20130228_0_929038x999506" unitRef="shares" decimals="INF" id="id_5950807_EAABAE2B-E268-4B76-85A6-F608444BE228_4001_1">258265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE719251--1410-Q0005_STD_0_20140731_0" unitRef="shares" decimals="INF" id="id_5950807_C095D765-E928-40BF-A4B7-8F2037BC5F1F_2_5">25953153</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:GovernmentContractReceivable contextRef="eol_PE719251--1410-Q0005_STD_0_20120229_0_926233x1126999_926437x923140_926744x1112837" unitRef="iso4217_USD" decimals="-5" id="id_5950807_8B90D036-89F3-4D59-81E6-81CB3AAAA16F_2001_0">39800000</us-gaap:GovernmentContractReceivable>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE719251--1410-Q0005_STD_0_20110531_0_926396x978559" unitRef="pure" decimals="INF" id="id_5950807_BE05A941-C7F6-45E8-A8E8-54EC3E01BD21_3001_3">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <ttph:DebtInstrumentMaximumBorrowingCapacity contextRef="eol_PE719251--1410-Q0005_STD_0_20110531_0_926396x978559" unitRef="iso4217_USD" decimals="-5" id="id_5950807_BE05A941-C7F6-45E8-A8E8-54EC3E01BD21_3001_0">8000000</ttph:DebtInstrumentMaximumBorrowingCapacity>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE719251--1410-Q0005_STD_0_20110531_0_926396x978559_932980x930400" unitRef="shares" decimals="INF" id="id_5950807_BE05A941-C7F6-45E8-A8E8-54EC3E01BD21_4001_8">1555815</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE719251--1410-Q0005_STD_0_20110531_0_926396x978559_932980x930400" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5950807_BE05A941-C7F6-45E8-A8E8-54EC3E01BD21_4001_10">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE719251--1410-Q0005_STD_0_20110531_0_926396x978559_932980x930400" unitRef="iso4217_USD_per_Right" decimals="INF" id="id_5950807_BE05A941-C7F6-45E8-A8E8-54EC3E01BD21_4001_9">0.2571</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE719251--1410-Q0005_STD_0_20140623_0_923791x1190397_933025x1575944" unitRef="shares" decimals="INF" id="id_5950807_BED7CAF5-5812-4A18-8627-49E2C8EFE761_2001_0">12354</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE719251--1410-Q0005_STD_0_20140623_0_923791x1190399_933025x1575944" unitRef="shares" decimals="INF" id="id_5950807_BED7CAF5-5812-4A18-8627-49E2C8EFE761_2002_0">11366</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE719251--1410-Q0005_STD_0_20060831_0_926233x925806" unitRef="shares" decimals="INF" id="id_5950807_C0F2E3A8-182E-4C63-A7D1-6F6D56F3DA73_2001_1">31379</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE719251--1410-Q0005_STD_0_20060831_0_929038x999506" unitRef="shares" decimals="INF" id="id_5950807_06DEE920-F3E2-4116-A801-6EF99B484469_2001_0">1128183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:GovernmentContractReceivable contextRef="eol_PE719251--1410-Q0005_STD_0_20110930_0_926233x1126999_926437x923140_926744x1070296" unitRef="iso4217_USD" decimals="-5" id="id_5950807_5B7AE169-0800-4774-BB28-1A9689719020_4001_2">13300000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="eol_PE719251--1410-Q0005_STD_0_20110930_0_926233x1126999_926744x1070296_928294x1262318" unitRef="iso4217_USD" decimals="-5" id="id_5950807_5B7AE169-0800-4774-BB28-1A9689719020_6001_4">7600000</us-gaap:GovernmentContractReceivable>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE719251--1410-Q0005_STD_0_20130630_0" unitRef="shares" decimals="-5" id="id_5950807_570C3778-B9DD-40DC-8F0B-8C0CCC3EF3EF_1002_2">20700000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE719251--1410-Q0005_STD_0_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_BB062D43-05B3-4FA2-86A7-4D9100189465_1001_4">0</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE719251--1410-Q0005_STD_0_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1002_31">77216000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_30">25909000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_5950807_9A53C01F-94D5-4AAD-AD78-7C1E0B16A492_3001_8">1383882</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_29">25909000</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_25">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5950807_17A785CA-D7D3-4BD8-8AEC-F2D8D8CE8ED5_3001_6">8.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_5950807_9A53C01F-94D5-4AAD-AD78-7C1E0B16A492_3001_6">3701914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_23">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5950807_17A785CA-D7D3-4BD8-8AEC-F2D8D8CE8ED5_3001_7">8.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="INF" id="id_5950807_9A53C01F-94D5-4AAD-AD78-7C1E0B16A492_3001_7">3524478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5950807_17A785CA-D7D3-4BD8-8AEC-F2D8D8CE8ED5_3001_8">3.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_28">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_27">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_22">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="shares" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_24">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:LoansPayableCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_15">4588000</us-gaap:LoansPayableCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_21">0</us-gaap:PreferredStockValue>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_13">5959000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_9F8D0026-87FE-4E8C-9AA4-7BB328E57A98_1_2">1132000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_9F8D0026-87FE-4E8C-9AA4-7BB328E57A98_1_3">7645000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F072016D-E8C0-4797-A203-23AB78BA7DF1_1_4">513000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_31">210076000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_12">6724000</us-gaap:AccountsPayableCurrent>
  <us-gaap:LoansPayableFairValueDisclosure contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-5" id="id_5950807_DFC26FBF-3CD2-44D3-9B6D-3C93FE28563F_1_0">8100000</us-gaap:LoansPayableFairValueDisclosure>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F072016D-E8C0-4797-A203-23AB78BA7DF1_1_3">199000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:LongTermLoansPayable contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_18">2890000</us-gaap:LongTermLoansPayable>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_16">17271000</us-gaap:LiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F072016D-E8C0-4797-A203-23AB78BA7DF1_1_1">1155000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_17">397000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_33">58395000</us-gaap:StockholdersEquity>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_32">-151707000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:CommonStockValue contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_26">26000</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_34">78953000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_9F8D0026-87FE-4E8C-9AA4-7BB328E57A98_1_1">3513000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_9F8D0026-87FE-4E8C-9AA4-7BB328E57A98_1_0">3000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_19" />
  <us-gaap:PrepaidInsurance contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_4D49C4F4-2F37-4D90-8076-0E2D669E2837_1_0">630000</us-gaap:PrepaidInsurance>
  <us-gaap:AssetsCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_5">78488000</us-gaap:AssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_7">199000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_8">29000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_5950807_E6E5DC65-7B8A-466E-B3D9-3A1A976BAA63_1_0">199000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:Assets contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_9">78953000</us-gaap:Assets>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3AB00857-C973-4225-80C9-B7F88A44C5DD_3001_4">20431000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_2">75371000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OtherPrepaidExpenseCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_4D49C4F4-2F37-4D90-8076-0E2D669E2837_1_4">81000</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_3">1343000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3AB00857-C973-4225-80C9-B7F88A44C5DD_3001_5">13342000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_E7E9201B-5824-4019-9CB9-9EF99F026EDC_1_0">151707000</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_4">1774000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3AB00857-C973-4225-80C9-B7F88A44C5DD_3001_3">20931000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_4D49C4F4-2F37-4D90-8076-0E2D669E2837_1_5">49000</us-gaap:OtherAssetsCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-5" id="id_5950807_2A12F2D5-AE08-4B7F-BC91-34AD41F9B74F_1001_0">11600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:GovernmentContractReceivableUnbilledAmounts contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-5" id="id_5950807_27E3B48F-2F0C-4D88-AEE7-4E76B003084D_1_0">0</us-gaap:GovernmentContractReceivableUnbilledAmounts>
  <us-gaap:PrepaidRent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_4D49C4F4-2F37-4D90-8076-0E2D669E2837_1_3">119000</us-gaap:PrepaidRent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_1_6">237000</us-gaap:PropertyPlantAndEquipmentNet>
  <ttph:UnamortizedDebtIssuanceCostAndDebtDiscountCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_9F8D0026-87FE-4E8C-9AA4-7BB328E57A98_1_5">129000</ttph:UnamortizedDebtIssuanceCostAndDebtDiscountCurrent>
  <ttph:UnamortizedDebtIssuanceCostAndDebtDiscountNonCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_9F8D0026-87FE-4E8C-9AA4-7BB328E57A98_1_8">38000</ttph:UnamortizedDebtIssuanceCostAndDebtDiscountNonCurrent>
  <ttph:AccruedClinicalExpenseCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F072016D-E8C0-4797-A203-23AB78BA7DF1_1_0">3447000</ttph:AccruedClinicalExpenseCurrent>
  <ttph:AccruedDrugSupplyAndDevelopmentCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F072016D-E8C0-4797-A203-23AB78BA7DF1_1_2">645000</ttph:AccruedDrugSupplyAndDevelopmentCurrent>
  <ttph:PrepaidManufacturingFeesCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_4D49C4F4-2F37-4D90-8076-0E2D669E2837_1_2">387000</ttph:PrepaidManufacturingFeesCurrent>
  <ttph:AmountPayableToLessorsInRespectOfDefaultOnRentalObligation contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="0" id="id_5950807_E6E5DC65-7B8A-466E-B3D9-3A1A976BAA63_1_3">159000</ttph:AmountPayableToLessorsInRespectOfDefaultOnRentalObligation>
  <ttph:PrepaidClinicalExpenses contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_4D49C4F4-2F37-4D90-8076-0E2D669E2837_1_1">508000</ttph:PrepaidClinicalExpenses>
  <ttph:LongTermDebtCurrentIncludingDebtDiscountAndIssuanceCosts contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_9F8D0026-87FE-4E8C-9AA4-7BB328E57A98_1_4">4717000</ttph:LongTermDebtCurrentIncludingDebtDiscountAndIssuanceCosts>
  <ttph:LongTermDebtNonCurrentIncludingDebtDiscountAndIssuanceCosts contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_9F8D0026-87FE-4E8C-9AA4-7BB328E57A98_1_7">2928000</ttph:LongTermDebtNonCurrentIncludingDebtDiscountAndIssuanceCosts>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0_924211x926224" unitRef="iso4217_USD" decimals="-3" id="id_5950807_FCB82176-7093-4FE6-BF15-D25F9867E879_6001_1">3255000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0_924211x926224_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_5950807_FCB82176-7093-4FE6-BF15-D25F9867E879_6002_1">3255000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0_924211x932359" unitRef="iso4217_USD" decimals="-3" id="id_5950807_FCB82176-7093-4FE6-BF15-D25F9867E879_7001_2">72116000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0_924211x932359_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_5950807_FCB82176-7093-4FE6-BF15-D25F9867E879_7002_2">72116000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <ttph:RevisedGrantsReceivable contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0_926233x1038577_926744x1070296" unitRef="iso4217_USD" decimals="-5" id="id_5950807_5B2F3895-5292-4ECE-AEE8-00FE4FEA926B_3001_2">800000</ttph:RevisedGrantsReceivable>
  <us-gaap:GovernmentContractReceivable contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0_926233x1126999_926744x1070296" unitRef="iso4217_USD" decimals="-5" id="id_5950807_5B7AE169-0800-4774-BB28-1A9689719020_1002_5">5800000</us-gaap:GovernmentContractReceivable>
  <ttph:RevisedContractReceivableDueInNextRollingTwelveMonths contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0_926233x1126999_926744x1070296" unitRef="iso4217_USD" decimals="-5" id="id_5950807_5B2F3895-5292-4ECE-AEE8-00FE4FEA926B_4001_0">7600000</ttph:RevisedContractReceivableDueInNextRollingTwelveMonths>
  <ttph:RevisedContractReceivableDueInNextRollingTwelveMonths contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0_926233x1126999_926744x1112837" unitRef="iso4217_USD" decimals="-5" id="id_5950807_A0681CA6-9A9C-49C3-AECB-E70BE3D86814_3001_0">22000000</ttph:RevisedContractReceivableDueInNextRollingTwelveMonths>
  <ttph:PotentialFuturePaymentsForRegulatoryMilestones contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0_926233x925806" unitRef="iso4217_USD" decimals="-5" id="id_5950807_848ECABA-DB9B-436E-A911-176B648F8837_1001_0">15100000</ttph:PotentialFuturePaymentsForRegulatoryMilestones>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0_926801x927260" unitRef="iso4217_USD" decimals="0" id="id_5950807_E6E5DC65-7B8A-466E-B3D9-3A1A976BAA63_1001_2">40000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0_926801x930315" unitRef="iso4217_USD" decimals="0" id="id_5950807_E6E5DC65-7B8A-466E-B3D9-3A1A976BAA63_2001_1">159000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0_929038x1056245" unitRef="shares" decimals="INF" id="id_5950807_EAABAE2B-E268-4B76-85A6-F608444BE228_1002_4">400147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE719251--1410-Q0005_STD_0_20140630_0_929038x999506" unitRef="shares" decimals="INF" id="id_5950807_06DEE920-F3E2-4116-A801-6EF99B484469_1003_3">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE719251--1410-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_BB062D43-05B3-4FA2-86A7-4D9100189465_2001_0">610000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE719251--1410-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2001_30">9079000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE719251--1410-Q0005_STD_0_20121231_0_926396x1061900_931308x1104289_932980x930400" unitRef="shares" decimals="INF" id="id_5950807_4EEC327D-1763-4C67-B92B-7829DBD0EB3D_6002_6">964605</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE719251--1410-Q0005_STD_0_20121231_0_926396x1061900_931308x1104289_932980x930400" unitRef="iso4217_USD_per_Right" decimals="INF" id="id_5950807_4EEC327D-1763-4C67-B92B-7829DBD0EB3D_6002_7">0.2571</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <ttph:DebtInstrumentAdditionalBorrowingCapacityAmount contextRef="eol_PE719251--1410-Q0005_STD_0_20121231_0_926396x1117504" unitRef="iso4217_USD" decimals="-5" id="id_5950807_0B861D5C-A061-4E68-A3D9-EA95BD44E5C7_5002_0">9200000</ttph:DebtInstrumentAdditionalBorrowingCapacityAmount>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_30">25629000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_29">25629000</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_25">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5950807_17A785CA-D7D3-4BD8-8AEC-F2D8D8CE8ED5_1001_2">5.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_5950807_9A53C01F-94D5-4AAD-AD78-7C1E0B16A492_1001_2">2844343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_23">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_28">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_27">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_22">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="shares" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_24">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:LoansPayableCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_15">5928000</us-gaap:LoansPayableCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_21">0</us-gaap:PreferredStockValue>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_13">5290000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F072016D-E8C0-4797-A203-23AB78BA7DF1_2_4">671000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_31">207503000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_12">1881000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F072016D-E8C0-4797-A203-23AB78BA7DF1_2_3">246000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:LongTermLoansPayable contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_18">4560000</us-gaap:LongTermLoansPayable>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_16">13191000</us-gaap:LiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F072016D-E8C0-4797-A203-23AB78BA7DF1_2_1">1554000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_17">327000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_33">87808000</us-gaap:StockholdersEquity>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_32">-119721000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_14">92000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_26">26000</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_34">105886000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_19" />
  <us-gaap:PrepaidInsurance contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_4D49C4F4-2F37-4D90-8076-0E2D669E2837_2_0">269000</us-gaap:PrepaidInsurance>
  <us-gaap:AssetsCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_5">105420000</us-gaap:AssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_7">199000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_8">32000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_5950807_E6E5DC65-7B8A-466E-B3D9-3A1A976BAA63_2_0">199000</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:Assets contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_9">105886000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_2">102712000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OtherPrepaidExpenseCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_4D49C4F4-2F37-4D90-8076-0E2D669E2837_2_4">30000</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_3">1706000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_4">1002000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3AB00857-C973-4225-80C9-B7F88A44C5DD_1001_2">23960000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_4D49C4F4-2F37-4D90-8076-0E2D669E2837_2_5">148000</us-gaap:OtherAssetsCurrent>
  <us-gaap:GovernmentContractReceivableUnbilledAmounts contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-5" id="id_5950807_27E3B48F-2F0C-4D88-AEE7-4E76B003084D_2_0">800000</us-gaap:GovernmentContractReceivableUnbilledAmounts>
  <us-gaap:PrepaidRent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_4D49C4F4-2F37-4D90-8076-0E2D669E2837_2_3">89000</us-gaap:PrepaidRent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F40E9E57-276F-4383-B1BE-4A7EB3DBB95C_2_6">235000</us-gaap:PropertyPlantAndEquipmentNet>
  <ttph:AccruedClinicalExpenseCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F072016D-E8C0-4797-A203-23AB78BA7DF1_2_0">1849000</ttph:AccruedClinicalExpenseCurrent>
  <ttph:AccruedDrugSupplyAndDevelopmentCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_F072016D-E8C0-4797-A203-23AB78BA7DF1_2_2">970000</ttph:AccruedDrugSupplyAndDevelopmentCurrent>
  <ttph:PrepaidManufacturingFeesCurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_4D49C4F4-2F37-4D90-8076-0E2D669E2837_2_2">4000</ttph:PrepaidManufacturingFeesCurrent>
  <ttph:AmountPayableToLessorsInRespectOfDefaultOnRentalObligation contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="0" id="id_5950807_E6E5DC65-7B8A-466E-B3D9-3A1A976BAA63_2_3">159000</ttph:AmountPayableToLessorsInRespectOfDefaultOnRentalObligation>
  <ttph:PrepaidClinicalExpenses contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_4D49C4F4-2F37-4D90-8076-0E2D669E2837_2_1">462000</ttph:PrepaidClinicalExpenses>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0_924211x926224" unitRef="iso4217_USD" decimals="-3" id="id_5950807_FCB82176-7093-4FE6-BF15-D25F9867E879_1001_3">2704000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0_924211x926224_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_5950807_FCB82176-7093-4FE6-BF15-D25F9867E879_1002_3">2704000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0_924211x932359" unitRef="iso4217_USD" decimals="-3" id="id_5950807_FCB82176-7093-4FE6-BF15-D25F9867E879_2001_4">100008000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0_924211x932359_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_5950807_FCB82176-7093-4FE6-BF15-D25F9867E879_2002_4">100008000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0_926801x927260" unitRef="iso4217_USD" decimals="0" id="id_5950807_E6E5DC65-7B8A-466E-B3D9-3A1A976BAA63_1002_2">40000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE719251--1410-Q0005_STD_0_20131231_0_926801x930315" unitRef="iso4217_USD" decimals="0" id="id_5950807_E6E5DC65-7B8A-466E-B3D9-3A1A976BAA63_2002_1">159000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <ttph:ClassOfWarrantOrRightCancelled contextRef="eol_PE719251--1410-Q0005_STD_1_20140623_0_923791x1190397_933025x1575944" unitRef="shares" decimals="INF" id="id_5950807_BED7CAF5-5812-4A18-8627-49E2C8EFE761_1001_2">14470</ttph:ClassOfWarrantOrRightCancelled>
  <ttph:ClassOfWarrantOrRightCancelled contextRef="eol_PE719251--1410-Q0005_STD_1_20140623_0_923791x1190399_933025x1575944" unitRef="shares" decimals="INF" id="id_5950807_BED7CAF5-5812-4A18-8627-49E2C8EFE761_1002_2">13312</ttph:ClassOfWarrantOrRightCancelled>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="pure" decimals="4" id="id_5950807_44E99F0C-1E8C-483C-B4B7-C699ABBA5BCD_2_2">0.5450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="shares" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_4_13">11263000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_16">-7247000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="pure" xsi:nil="true" id="id_5950807_44E99F0C-1E8C-483C-B4B7-C699ABBA5BCD_2_10" />
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_4_12">-0.73</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="pure" decimals="4" id="id_5950807_44E99F0C-1E8C-483C-B4B7-C699ABBA5BCD_2_3">0.5873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="pure" decimals="4" id="id_5950807_44E99F0C-1E8C-483C-B4B7-C699ABBA5BCD_2_8">0.0091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="pure" decimals="4" id="id_5950807_44E99F0C-1E8C-483C-B4B7-C699ABBA5BCD_2_9">0.0130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:Revenues contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_4_0">6422000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_12">-176000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_4_14">-8217000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_34">115000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_4_9">263000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_25">1409000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_4_7">2000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_4_5">-7581000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestPaid contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_33">561000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_11">460000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_4_10">-636000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_4_11">-8217000</us-gaap:NetIncomeLoss>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_18">22000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_BB062D43-05B3-4FA2-86A7-4D9100189465_1_2">263000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_21">73805000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_4_3">2981000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_4">177000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_28">75406000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_36">79832000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_15">-699000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_6">-263000</us-gaap:AdjustmentOfWarrantsGrantedForServices>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_7">335000</us-gaap:ShareBasedCompensation>
  <us-gaap:OperatingCostsAndExpenses contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_4_4">14003000</us-gaap:OperatingCostsAndExpenses>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_3">72000</us-gaap:DepreciationAndAmortization>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_29">68137000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_19">-22000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_14">1135000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_4_8">901000</us-gaap:InterestExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_13">392000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:AccretionExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_5">105000</us-gaap:AccretionExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_4_2">11022000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_27">10000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_24">3000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3CF4E30D-3DA0-4B50-8DAE-30D89729646F_4_2">335000</us-gaap:AllocatedShareBasedCompensationExpense>
  <ttph:ReclassificationOfConvertiblePreferredStockWarrantsToCommonStockWarrants contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_37">462000</ttph:ReclassificationOfConvertiblePreferredStockWarrantsToCommonStockWarrants>
  <ttph:ReclassificationOfDeferredFinancingCostsToAdditionalPaidInCapital contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_2_38">1261000</ttph:ReclassificationOfDeferredFinancingCostsToAdditionalPaidInCapital>
  <us-gaap:RevenueFromGrants contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0_926233x1038577_926744x1070296" unitRef="iso4217_USD" decimals="0" id="id_5950807_1396B07E-D0B0-4FE6-B41D-D74713C5E576_1004_0">231000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0_926233x1038577_926744x1112837" unitRef="iso4217_USD" decimals="-5" id="id_5950807_9E6F3154-FD7F-4E0F-87A6-7DE8762C5F98_1004_0">1200000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0_926233x1126999_926744x1112837" unitRef="iso4217_USD" decimals="-5" id="id_5950807_F1922899-5E4E-4DEF-A288-CA6496B3A03C_1004_0">5000000</us-gaap:RevenueFromGrants>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0_926437x923140" id="id_5950807_44E99F0C-1E8C-483C-B4B7-C699ABBA5BCD_1002_6">P6Y1M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0_926437x932953" id="id_5950807_44E99F0C-1E8C-483C-B4B7-C699ABBA5BCD_2002_5">P5Y9M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0_927015x925832" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3CF4E30D-3DA0-4B50-8DAE-30D89729646F_1004_1">183000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0_927015x928963" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3CF4E30D-3DA0-4B50-8DAE-30D89729646F_2004_0">152000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0_928305x924898" unitRef="shares" decimals="INF" id="id_5950807_A11CADE4-655C-4EDB-86DB-EED9A07BA430_1002_1">2686892</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE719251--1410-Q0005_STD_181_20130630_0_928305x929614" unitRef="shares" decimals="INF" id="id_5950807_A11CADE4-655C-4EDB-86DB-EED9A07BA430_2002_0">104107</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <dei:EntityRegistrantName contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_C095D765-E928-40BF-A4B7-8F2037BC5F1F_1_1">TETRAPHASE PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_C75BECE2-F74F-482E-818C-1F0B1B3A8946_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_C095D765-E928-40BF-A4B7-8F2037BC5F1F_1_4">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_C75BECE2-F74F-482E-818C-1F0B1B3A8946_1_3">2014</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_C75BECE2-F74F-482E-818C-1F0B1B3A8946_1_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_C75BECE2-F74F-482E-818C-1F0B1B3A8946_1_2">2014-06-30</dei:DocumentPeriodEndDate>
  <dei:EntityIncorporationDateOfIncorporation contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_759126E3-BEF4-44DC-89E3-A03BB8A9ECEA_1_0">2006-07-07</dei:EntityIncorporationDateOfIncorporation>
  <dei:EntityCentralIndexKey contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_C095D765-E928-40BF-A4B7-8F2037BC5F1F_1_2">0001373707</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_C095D765-E928-40BF-A4B7-8F2037BC5F1F_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_C75BECE2-F74F-482E-818C-1F0B1B3A8946_1_4">Q2</dei:DocumentFiscalPeriodFocus>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_39E8F00A-E4FF-4E0C-9801-ECC4E971B127_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;(7) Stock-based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In August&amp;#xA0;2006, the Company adopted the Tetraphase
 Pharmaceuticals, Inc. Stock Incentive Plan (the &amp;#x201C;2006
 Plan&amp;#x201D;) under which it was able to grant incentive stock
 options, nonqualified stock options, restricted stock, and stock
 grants to purchase up to 1,128,183 shares of Common Stock. In May
 2010, the Company amended the plan to increase the number of shares
 of Common Stock issuable under the 2006 Plan to 1,853,288. The
 options expire ten years after the grant date. As of June&amp;#xA0;30,
 2014, no shares were available for future issuance under the 2006
 Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In February 2013, the Company&amp;#x2019;s board of directors and
 stockholders approved, effective upon the closing of the IPO, the
 2013 Stock Incentive Plan (the &amp;#x201C;2013 Plan&amp;#x201D;). Under the
 2013 Plan, the Company may grant incentive stock options,
 nonstatutory stock options, stock appreciation rights, restricted
 stock, restricted stock units and other stock-based awards for the
 purchase of that number of shares of Common Stock equal to the sum
 of (i)&amp;#xA0;1,688,777 shares of Common Stock, (ii)&amp;#xA0;258,265
 shares of Common Stock that were reserved for issuance under the
 2006 Plan that remained available for issuance under the 2006 Plan
 upon the closing of the IPO, (iii)&amp;#xA0;any shares of Common Stock
 subject to awards under the 2006 Plan which awards expire,
 terminate or are otherwise surrendered, canceled, forfeited or
 repurchased by the Company without having been fully exercised or
 resulting in any Common Stock being issued. In addition, the number
 of shares of Common Stock that may be issued under the 2013 Plan is
 subject to automatic annual increases, to be added on
 January&amp;#xA0;1 of each year from January&amp;#xA0;1, 2014 through and
 including January&amp;#xA0;1, 2023, equal to the number of shares that
 is the lesser of (a)&amp;#xA0;3,000,000, (b)&amp;#xA0;4% of the then
 outstanding shares of Common Stock or (c)&amp;#xA0;an amount determined
 by the Company&amp;#x2019;s board of directors. In January 2014, the
 number of shares authorized for issuance under the 2013 Plan
 increased by 1,025,171 shares. As of June&amp;#xA0;30, 2014, 400,147
 shares were available for future issuance under the 2013 Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Terms of stock award agreements, including vesting requirements,
 are determined by the board of directors, subject to the provisions
 of the 2013 Plan. Options granted by the Company typically vest
 over a four year period. Certain of the options are subject to
 acceleration of vesting in the event of certain change of control
 transactions. The options are exercisable from the date of grant
 for a period of ten years. For options granted prior to the
 Company&amp;#x2019;s IPO, the exercise price equaled the estimated fair
 value of the Common Stock as determined by the board of directors
 on the date of grant. For options granted subsequent to the
 Company&amp;#x2019;s IPO, the exercise price equaled the closing price
 of the Company&amp;#x2019;s stock on the NASDAQ Global Market on the
 date of grant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes stock option activity at
 June&amp;#xA0;30, 2014 and changes during the six months then ended is
 presented in the table and narrative below (in thousands except
 share and per share data):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&lt;br /&gt;
 Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
 Average&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual&lt;br /&gt;
 Term&amp;#xA0;(years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 Intrinsic&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options outstanding at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,844,343&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,960&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,233,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.06&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(256,152&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.43&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(119,927&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.39&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options outstanding at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,701,914&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,931&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options vested or expected to vest at June&amp;#xA0;30, 2014 (1)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,524,478&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,431&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options exercisable at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,383,882&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,342&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(1)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;This represents the number of vested
 options as of June&amp;#xA0;30, 2014, plus the number of unvested
 options that the Company estimated as of June&amp;#xA0;30, 2014 that
 would vest, based on the unvested options at June&amp;#xA0;30, 2014, as
 adjusted for the estimated forfeiture rate of 5.0%.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The aggregate intrinsic value in the table above represents the
 value (the difference between the Company&amp;#x2019;s closing common
 stock price on the last trading day during the six months ended
 June&amp;#xA0;30, 2014 and the exercise price of the options,
 multiplied by the number of in-the-money options) that would have
 been received by the option holders had all option holders
 exercised their options on June&amp;#xA0;30, 2014.&amp;#xA0;As of
 June&amp;#xA0;30, 2014, approximately $11.6 million of total
 unrecognized stock-based compensation expense related to unvested
 stock options is expected to be recognized over a weighted-average
 period of 3.0 years.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Since the Company completed its IPO on March&amp;#xA0;25, 2013, it has
 not had sufficient historical data to support a calculation of
 volatility and expected life. As such, the Company has used a
 weighted-average volatility considering the Company&amp;#x2019;s own
 volatility, and the volatilities of a representative group of
 publicly traded companies.&amp;#xA0;For purposes of identifying similar
 entities, the Company selected a group of publicly traded companies
 based on their disease focus, stage of development, number of
 compounds in clinical trials and number of years as a
 publicly-traded company. The risk-free interest rate is based on
 the U.S. Treasury yield curve in effect at the time of grant,
 commensurate with the expected life assumption. The expected life
 of stock options granted represents the weighted-average period of
 time that stock options granted are expected to be outstanding
 determined using the simplified method for employee grants. For
 nonemployee grants, the expected life is equal to the remaining
 contractual term. The expected life is applied to the stock option
 grant group as a whole, as the Company does not expect
 substantially different exercise or post-vesting termination
 behavior among its employee population.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During the three and six months ended June&amp;#xA0;30, 2014 and 2013,
 respectively, the assumptions used in the Black-Scholes pricing
 model for new employee grants were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="3" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Volatility factor&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;53.41-53.83%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;58.41-58.73%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.31-6.11&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.97-6.11&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rates&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.73-2.05%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.91-1.30%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="3" align="center"&gt;&lt;b&gt;Six&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;June
 30,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Volatility factor&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;53.41-53.96%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;54.50-58.73%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.31-6.11&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.82-6.11&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rates&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.71-2.13%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0.91-1.30%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Stock-based compensation expense recognized in the Company&amp;#x2019;s
 condensed consolidated statements of operations for stock options
 granted during the periods presented was as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&lt;br /&gt;
 Ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six&amp;#xA0;Months&lt;br /&gt;
 Ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;484&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;152&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,355&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;183&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,066&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;280&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;335&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 
 
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_1413A5DB-A1DF-463A-9159-893592FC7943_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements Issued and
 Adopted&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 During the quarter ended&amp;#xA0;June&amp;#xA0;30, 2014, the Financial
 Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;) issued Accounting
 Standards Update (&amp;#x201C;ASU&amp;#x201D;) No.&amp;#xA0;2014-09, Revenue from
 Contracts with Customers (Topic 606), which supersedes all existing
 revenue recognition requirements, including most industry-specific
 guidance. The new standard requires a company to recognize revenue
 when it transfers goods or services to customers in an amount that
 reflects the consideration that the company expects to receive for
 those goods or services. The new standard will be effective for the
 Company on January&amp;#xA0;1, 2017. The Company is currently
 evaluating the potential impact that this update may have on the
 Company&amp;#x2019;s financial position and results of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 During the quarter ended&amp;#xA0;June&amp;#xA0;30, 2014, the FASB issued
 ASU 2014-10, which simplifies financial reporting for development
 stage entities by eliminating requirements specific to development
 stage entities. As a result, entities in a development stage will
 no longer need to present inception-to-date information about
 income statement line items, cash flows, and equity transactions.
 Instead, the new guidance clarifies how these entities should
 tailor existing disclosures to explain the risks and uncertainties
 related to their activities. This update is effective for annual
 periods beginning after December&amp;#xA0;15, 2014, and early
 application is permitted for any annual or interim period for which
 the entity&amp;#x2019;s financial statements have not yet been issued.
 The Company adopted this guidance prior to issuing the financial
 statements in the Form 10-Q for the three and six months ended
 June&amp;#xA0;30, 2014. The adoption of ASU 2014-10 impacted disclosure
 only and did not have any impact on the Company&amp;#x2019;s financial
 position or results of operations.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="Segment" decimals="INF" id="id_5950807_80F74DCF-D4E0-46F7-A58D-736D4C9EBF00_1_0">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_9648FB0B-7B4D-41CC-848E-E374912A286D_3001_4">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_1B11D00C-9886-4620-8E11-41926921ADB8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company applies the provisions of Accounting Standards
 Codification (&amp;#x201C;ASC&amp;#x201D;) 718,&lt;i&gt;&amp;#xA0;Compensation-Stock
 Compensation&lt;/i&gt; to stock-based awards.&amp;#xA0;Under ASC 718, the
 Company determines equity-based compensation at the grant date
 using the Black-Scholes option pricing model to estimate fair
 value. The Company recognizes the value of the award that is
 ultimately expected to vest as an expense on a straight-line basis
 over the requisite service period using the estimated fair market
 value of the stock. Any changes to the estimated forfeiture rates
 are accounted for prospectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_717FBD28-CBCD-4366-A0EE-2FED17AAB475_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s financial instruments consist principally of
 cash and cash equivalents, accounts receivable, accounts payable,
 accrued liabilities, and term loan payable. Fair value measurements
 are classified and disclosed in one of the following three
 categories:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="1%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="92%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Quoted prices in active markets for identical
 assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Inputs other than Level&amp;#xA0;1 that are
 observable, either directly or indirectly, such as quoted prices
 for similar assets or liabilities; quoted prices in markets that
 are not active; or other inputs that are observable or can be
 corroborated by observable market data for substantially the full
 term of the assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Unobservable inputs that are supported by little
 or no market activity and that are significant to the fair value of
 the assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Financial instruments measured at fair value as of June&amp;#xA0;30,
 2014 and December&amp;#xA0;31, 2013 are classified below based on the
 three fair value hierarchy tiers described above (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Fair Value Measurements at&lt;br /&gt;
 Reporting Date Using&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Balance&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;June&amp;#xA0;30, 2014&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,255&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,255&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Money market funds, included in cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,704&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,704&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Money market funds, included in cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100,008&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100,008&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company measures cash equivalents at fair value on a recurring
 basis. The fair value of cash equivalents is determined based on
 &amp;#x201C;Level 1&amp;#x201D; inputs, which consist of quoted prices in
 active markets for identical assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of the Company&amp;#x2019;s term loan payable is
 determined using current applicable rates for similar instruments
 as of the balance sheet date. The Company&amp;#x2019;s term loan payable
 is a Level 3 liability within the fair value hierarchy. The fair
 value of the Company&amp;#x2019;s term loan payable at June&amp;#xA0;30,
 2014, computed pursuant to a discounted cash flow technique using
 the effective interest rate under the loan, is $8.1 million. The
 effective interest rate considers the fair value of the warrant
 issued in connection with the loan, loan issuance costs and the
 deferred charge.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of the preferred stock warrant liability as of
 March&amp;#xA0;25, 2013 was determined based on
 &amp;#x201C;Level&amp;#xA0;3&amp;#x201D; inputs utilizing the Black-Scholes
 option pricing model (Note 6).&amp;#xA0;On March&amp;#xA0;25, 2013, upon
 completion of the Company&amp;#x2019;s initial public offering
 (&amp;#x201C;IPO&amp;#x201D;), the warrants to purchase preferred stock
 converted into warrants to purchase common stock and the Company
 reclassified the fair value of the warrants as of March&amp;#xA0;25,
 2013 to additional paid-in capital. The following table presents
 activity in the preferred stock warrant liability during the six
 months ended June&amp;#xA0;30, 2013 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="90%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Balance&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Fair value at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Value of warrants issued in 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;115&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Decrease in fair value recognized in net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(263&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Reclassification of fair value to additional paid-in capital&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(462&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Fair value at June&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_850AD3D6-497D-4129-9593-D3A2369D33E4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s revenue is derived from its subcontracts with
 CUBRC under the BARDA Contract and the NIAID Contract and its
 subaward under the NIAID Grant (Note 3). The Company recognizes
 revenue under these best-efforts, cost-reimbursable and
 cost-plus-fixed-fee subcontracts and subaward as the Company
 performs services under the subcontracts and subaward so long as a
 subcontract and subaward has been executed and the fees for these
 services are fixed or determinable, legally billable and reasonably
 assured of collection. Recognized amounts reflect the
 Company&amp;#x2019;s partial performance under the subcontracts and
 subaward and equal direct and indirect costs incurred plus fixed
 fees, where applicable. The Company does not recognize revenue
 under these arrangements for amounts related to contract periods
 where funding is not yet committed as amounts above committed
 funding thresholds would not be considered fixed or determinable or
 reasonably assured of collection. Revenues and expenses under these
 arrangements are presented gross on the condensed consolidated
 statements of operations and comprehensive loss as the Company has
 determined it is the primary obligor under these arrangements
 relative to the research and development services it performs as
 lead technical expert.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenue under the Company&amp;#x2019;s subcontract with respect to the
 BARDA Contract is earned under a cost-reimbursable contract through
 which the Company is reimbursed for direct costs incurred plus
 allowable indirect costs. Billings under the Company&amp;#x2019;s
 subcontract under the BARDA Contract are based on approved
 provisional indirect billing rates that permit recovery of
 allowable fringe benefits, overhead and general and administrative
 expenses. During the three months ended June&amp;#xA0;30, 2014 and
 2013, the Company recognized revenue of $0.8 million and $3.1
 million, respectively, from the Company&amp;#x2019;s subcontract under
 the BARDA Contract. During the six months ended June&amp;#xA0;30, 2014
 and 2013, the Company recognized revenue of $2.6 million and $5.0
 million, respectively, from the Company&amp;#x2019;s subcontract under
 the BARDA Contract.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenue under the Company&amp;#x2019;s subcontract with respect to the
 NIAID Contract is earned under a cost-plus-fixed-fee contract
 through which the Company is reimbursed for direct costs incurred
 plus allowable indirect costs and a fixed-fee earned. Billings
 under the Company&amp;#x2019;s subcontract under the NIAID Contract are
 based on approved provisional indirect billing rates that permit
 recovery of allowable fringe benefits, overhead and general and
 administrative expenses and a fixed fee. During the three months
 ended June&amp;#xA0;30, 2014 and 2013, the Company recognized revenue
 of $0.4 million and $0.5 million, respectively, from the
 Company&amp;#x2019;s subcontract under the NIAID Contract. During the
 six months ended June&amp;#xA0;30, 2014 and 2013, the Company
 recognized revenue of $1.0 million and $1.2 million, respectively,
 from the Company&amp;#x2019;s subcontract under the NIAID Contract.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenue under the Company&amp;#x2019;s subaward with respect to the
 NIAID Grant is earned under a cost-reimbursable contract through
 which the Company is reimbursed for direct costs incurred plus
 allowable indirect costs. Billings under the Company&amp;#x2019;s
 subaward under the NIAID Grant are based on approved provisional
 indirect billing rates that permit recovery of allowable fringe
 benefits and general and administrative expenses. During the three
 months ended June&amp;#xA0;30, 2014 and 2013, the Company recognized
 revenue of $32,000, and $78,000, respectively, from the
 Company&amp;#x2019;s subaward under the NIAID Grant. During the six
 months ended June&amp;#xA0;30, 2014 and 2013, the Company recognized
 revenue of $89,000, and $231,000, respectively, from the
 Company&amp;#x2019;s subaward under the NIAID Grant.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="pure" decimals="4" id="id_5950807_44E99F0C-1E8C-483C-B4B7-C699ABBA5BCD_1_2">0.5341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_A1CF1579-8388-4D17-9B24-B56DB59EA42A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes stock option activity at
 June&amp;#xA0;30, 2014 and changes during the six months then ended is
 presented in the table and narrative below (in thousands except
 share and per share data):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
 Average&lt;br /&gt;
 Exercise&lt;br /&gt;
 Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
 Average&lt;br /&gt;
 Remaining&lt;br /&gt;
 Contractual&lt;br /&gt;
 Term&amp;#xA0;(years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
 Intrinsic&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options outstanding at December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,844,343&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,960&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,233,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.06&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(256,152&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.43&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(119,927&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.39&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options outstanding at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,701,914&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,931&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options vested or expected to vest at June&amp;#xA0;30, 2014 (1)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,524,478&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,431&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options exercisable at June&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,383,882&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.93&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,342&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(1)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;This represents the number of vested
 options as of June&amp;#xA0;30, 2014, plus the number of unvested
 options that the Company estimated as of June&amp;#xA0;30, 2014 that
 would vest, based on the unvested options at June&amp;#xA0;30, 2014, as
 adjusted for the estimated forfeiture rate of 5.0%.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_A630B508-D615-4905-9E6B-28EA0DECF50F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Comprehensive Loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Comprehensive loss consists of net income or loss and changes in
 equity during a period from transactions and other events and
 circumstances generated from non-owner sources. The Company&amp;#x2019;s
 net loss equals comprehensive loss for all periods presented.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_1D219310-4421-447D-92CD-663935BABABE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 At June&amp;#xA0;30, 2014 and December&amp;#xA0;31, 2013 the Company had
 $199,000 in restricted cash deposits with a bank, of which $159,000
 is collateral for a letter of credit issued to the landlord of the
 Company&amp;#x2019;s leased facility. If the Company defaults on its
 rental obligations, $159,000 will be payable to the lessor of the
 leased facility. In addition, the Company has $40,000 in restricted
 cash to secure the Company&amp;#x2019;s corporate credit card issued
 through the same bank.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5950807_17A785CA-D7D3-4BD8-8AEC-F2D8D8CE8ED5_5001_5">10.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_79550A5B-02B3-41A0-93EB-96696C20C91F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The amounts in the table below were excluded from the calculation
 of diluted weighted-average shares outstanding, prior to the use of
 the treasury stock method, due to their anti-dilutive effect:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;104,107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,701,914&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,686,892&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_9648FB0B-7B4D-41CC-848E-E374912A286D_3001_3">P8Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_AC299DEE-CFFC-4CA7-9B0B-F0D4C716D760_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company considers events or transactions that occur after the
 balance sheet date but prior to the issuance of the financial
 statements to provide additional evidence relative to certain
 estimates or to identify matters that require additional
 disclosure.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="shares" decimals="INF" id="id_5950807_9A53C01F-94D5-4AAD-AD78-7C1E0B16A492_5001_3">1233650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ReceivablesPolicyTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_770595E8-DF27-4832-8359-CA4F85F0329C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In September 2011, the National Institutes of Health&amp;#x2019;s
 (&amp;#x201C;NIH&amp;#x201D;) National Institute of Allergy and Infectious
 Diseases (&amp;#x201C;NIAID&amp;#x201D;) division awarded a contract of up to
 $35.8 million over a five-year term for the development of TP-271,
 a preclinical compound, for respiratory disease caused by bacterial
 biothreat pathogens (&amp;#x201C;NIAID Contract&amp;#x201D;) (Note 3). The
 Company is collaborating with CUBRC Inc. (&amp;#x201C;CUBRC&amp;#x201D;), an
 independent, not for profit, research corporation that specializes
 in U.S. government-based contracts, on this NIAID Contract and has
 entered into a subcontract with CUBRC that could potentially
 provide funding to the Company of up to approximately $13.3 million
 over the five-year term, including committed funding of
 $7.6&amp;#xA0;million from the initial contract date through
 September&amp;#xA0;30, 2016, of which $5.8 million had been received by
 the Company through June&amp;#xA0;30, 2014. In addition during 2011,
 the Company was a subawardee under a separate grant from the NIAID
 (&amp;#x201C;NIAID Grant&amp;#x201D;) (Note 3).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In January 2012 the Biomedical Advanced Research and Development
 Authority (&amp;#x201C;BARDA&amp;#x201D;), an agency of the U.S. Department
 of Health and Human Services, awarded a contract of up to $67.0
 million for the development of eravacycline as a potential
 countermeasure for the treatment of disease caused by bacterial
 biothreat pathogens (&amp;#x201C;BARDA Contract&amp;#x201D;). The Company is
 also collaborating with CUBRC on the BARDA Contract and has entered
 into a subcontract with CUBRC that could potentially provide
 funding to the Company of up to approximately $39.8 million,
 including committed funding of $22.0 million from the initial
 contract date through January&amp;#xA0;31, 2016, of which $14.3 million
 had been received by the Company through June&amp;#xA0;30, 2014
 (Note&amp;#xA0;3).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Accounts receivable at June&amp;#xA0;30, 2014 and December&amp;#xA0;31,
 2013 represent amounts due from CUBRC under the Company&amp;#x2019;s
 subcontracts under the NIAID Contract and the BARDA Contract and
 under the Company&amp;#x2019;s subaward under the NIAID Grant. The
 Company&amp;#x2019;s practice is to bill the prime contractor, CUBRC,
 amounts for which the Company has been invoiced by third parties in
 the case of contract research or subcontractor costs or for
 internal costs incurred. Expenses directly associated with the
 Company&amp;#x2019;s NIAID and BARDA Contracts and NIAID Grant that have
 been accrued at the end of the reporting period are not billed to
 the prime contractor until third party invoices have been received
 or until internal costs have been paid. There was no unbilled
 accounts receivable balance at June&amp;#xA0;30, 2014. Unbilled
 accounts receivable was $0.8 million at December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_D3C9CCA4-D15A-4899-8FC8-3AD549F32623_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Financial instruments measured at fair value as of June&amp;#xA0;30,
 2014 and December&amp;#xA0;31, 2013 are classified below based on the
 three fair value hierarchy tiers described above (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Fair Value Measurements at&lt;br /&gt;
 Reporting Date Using&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Balance&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;June&amp;#xA0;30, 2014&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,255&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,255&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Money market funds, included in cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,704&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,704&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Money market funds, included in cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100,008&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100,008&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_7A76B26B-A42E-4480-BD49-A77F270F1172_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The condensed consolidated financial statements include the
 accounts of the Company and its wholly owned subsidiary, Tetraphase
 Securities Corporation, a Massachusetts Securities Corporation. All
 significant intercompany balances and transactions have been
 eliminated in consolidation.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_C022FD1C-4F1F-4205-AD45-548B3F980DBE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Accrued expenses at June&amp;#xA0;30, 2014 and December&amp;#xA0;31, 2013
 consisted of the following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Clinical trial related&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,447&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,849&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Salaries and benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,155&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,554&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Drug supply and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;645&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;970&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Professional fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;199&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;246&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;513&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;671&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,959&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,290&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_A8F843A6-900F-4E69-AD45-612AABF87B6C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Future principal payments on the Term Loan and the 2012 Term Loan
 are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="89%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2014 (6 months remaining)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,513&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,132&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total term loan payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,645&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Current term loan payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,717&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less debt discount and issuance costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(129&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Current term loan payable (net)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,588&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Term loan payable, less current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,928&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less debt discount and issuance costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(38&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Term loan payable, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,890&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="shares" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_3_13">25790000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5950807_17A785CA-D7D3-4BD8-8AEC-F2D8D8CE8ED5_5001_3">14.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_16">-24526000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:LongTermDebtTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_FC1BC8B8-8046-4D84-ACD6-50833231B7EA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;(6) Long-Term Debt&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In May 2011, the Company executed a Loan and Security Agreement
 with Silicon Valley Bank and Oxford Finance (the &amp;#x201C;Term
 Loan&amp;#x201D;), which provided for up to $8.0 million of funding, to
 be made available in two tranches. The Company borrowed the $8.0
 million in two tranches during the year ended December&amp;#xA0;31,
 2011. The Term Loan bears interest at 10%&amp;#xA0;per annum and
 provides for a final payment of 2.75% of the original principal due
 at the maturity date of November&amp;#xA0;1, 2014. Under the terms of
 the Term Loan, the Company was only required to pay interest (and
 not principal) through February&amp;#xA0;28, 2012. Each tranche is
 being repaid in 33 monthly payments of equal principal, plus
 accrued interest, after the interest only period that ended on
 February&amp;#xA0;28, 2012. The final payment of 2.75% will be due at
 the same time as the last loan payment. The Term Loan matures on
 November&amp;#xA0;1, 2014. In connection with the entry into the Loan
 and Security Agreement, the Company issued to the lenders 10-year
 warrants to purchase an aggregate of 1,555,815 shares of Series C
 Preferred Stock, par value $0.001 per share (the &amp;#x201C;Series C
 Preferred Stock&amp;#x201D;) at a price of $0.2571 per share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In December 2012, the Company entered into an amendment to the Term
 Loan (the &amp;#x201C;2012 Term Loan&amp;#x201D;) to provide for up to an
 additional $9.2&amp;#xA0;million in funding, to be made available in
 two tranches. The Company borrowed the first tranche totaling $6.2
 million under the 2012 Term Loan in December&amp;#xA0;2012 (&amp;#x201C;2012
 Term A Loan&amp;#x201D;) and borrowed the remaining $3.0 million in
 February 2013 (&amp;#x201C;2012 Term B Loan&amp;#x201D;). Both the 2012 Term
 A Loan and the 2012 Term B Loan bear interest at 9%&amp;#xA0;per
 annum.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company was only required to pay interest (and not principal)
 for the first six months of each tranche of the 2012 Term Loan.
 Each tranche of the 2012 Term Loan is being repaid in 33 equal
 monthly payments of principal, plus accrued interest, after the
 interest only period. An additional payment of 2.90% of the
 original principal amount of each tranche will be due at the same
 time as the last loan payment for the tranche. The 2012 Term A Loan
 matures on March&amp;#xA0;1, 2016. In connection with the funding of
 the 2012 Term A Loan, the Company issued to the lenders 10-year
 warrants to purchase an aggregate of 964,605 shares of Series C
 Preferred Stock with an exercise price of $0.2571 per share. The
 2012 Term B Loan matures on May&amp;#xA0;1, 2016. In connection with
 the funding of the 2012 Term B Loan, in February 2013, the warrant
 the Company issued to Silicon Valley Bank automatically became
 exercisable for an additional 233,372 shares of Series C Preferred
 Stock. In addition, the Company issued to Oxford Finance a 10-year
 warrant to purchase an additional 233,372 shares of Series C
 Preferred Stock with an exercise price of $0.2571 per share. In
 connection with the completion of the Company&amp;#x2019;s IPO, the
 warrants to purchase Series C Preferred Stock were converted into
 warrants to purchase common stock of the Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On June&amp;#xA0;23, 2014, Silicon Valley Bank exercised its warrants
 under the Term Loan and 2012 Term A Loan described above pursuant
 to the cashless exercise feature of the warrants. In connection
 with the exercise of the warrants under the Term Loan, the Company
 issued 12,354 shares of the Company&amp;#x2019;s common stock. Warrants
 to purchase 14,470 shares of common stock were cancelled as payment
 for the aggregate exercise price of the warrants. In connection
 with the exercise of the warrants under the 2012 Term A Loan, the
 Company issued 11,366 shares of the Company&amp;#x2019;s common stock.
 Warrants to purchase 13,312 shares of common stock were cancelled
 as payment for the aggregate exercise price of the warrants.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Term Loan and the 2012 Term Loan are collateralized by a
 blanket lien on all corporate assets, excluding intellectual
 property, and by a negative pledge of the Company&amp;#x2019;s
 intellectual property. The Term Loan and the 2012 Term Loan contain
 customary default provisions that include material adverse events,
 as defined therein. The Company has determined that the risk of
 subjective acceleration under the material adverse events clause is
 remote and therefore has classified the outstanding principal in
 current and long-term liabilities based on scheduled principal
 payments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Future principal payments on the Term Loan and the 2012 Term Loan
 are as follows (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="89%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2014 (6 months remaining)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,513&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,132&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total term loan payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,645&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Current term loan payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,717&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less debt discount and issuance costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(129&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Current term loan payable (net)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,588&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Term loan payable, less current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,928&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less debt discount and issuance costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(38&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Term loan payable, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,890&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_CB66E3F3-6699-46EE-94FB-F517E6458870_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment, Net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment are stated at cost, less accumulated
 depreciation and amortization. Depreciation and amortization are
 provided using the straight-line method over the estimated useful
 lives of the respective assets, which is generally three to five
 years. Leasehold improvements are amortized over the shorter of the
 lease term or the estimated useful economic lives of the related
 assets.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="pure" xsi:nil="true" id="id_5950807_44E99F0C-1E8C-483C-B4B7-C699ABBA5BCD_1_10" />
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_7171EEE1-40D9-4464-B80A-F8C9C913EE59_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company considers all highly liquid investments with maturities
 of three months or less from the date of purchase to be cash
 equivalents. Cash and cash equivalents at June&amp;#xA0;30, 2014 and
 December&amp;#xA0;31, 2013 consisted of cash and money market
 funds.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_4B89E274-524E-411E-A5EB-EEACDBE52C9F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;(5) Accrued Expenses&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Accrued expenses at June&amp;#xA0;30, 2014 and December&amp;#xA0;31, 2013
 consisted of the following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Clinical trial related&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,447&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,849&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Salaries and benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,155&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,554&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Drug supply and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;645&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;970&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Professional fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;199&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;246&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;513&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;671&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,959&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,290&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_3_12">-1.24</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5950807_17A785CA-D7D3-4BD8-8AEC-F2D8D8CE8ED5_5001_4">1.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:StartUpActivitiesCostPolicy contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_EA6449AC-5A0D-4686-81A7-BDCFABC46658_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Organizational Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 All organizational costs are expensed as incurred.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StartUpActivitiesCostPolicy>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_2A12F2D5-AE08-4B7F-BC91-34AD41F9B74F_1_1">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="pure" decimals="4" id="id_5950807_44E99F0C-1E8C-483C-B4B7-C699ABBA5BCD_1_3">0.5396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_FE5C5E10-5B6A-4A8D-8BC1-18B2A81A6479_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Research and development costs are charged to expense as incurred
 and include, but are not limited to:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;personnel-related expenses, including
 salaries, benefits, and stock-based compensation expense;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;expenses incurred under agreements
 with contract research organizations, contract manufacturing
 organizations and consultants that conduct clinical trials and
 preclinical studies;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;payments made under the
 Company&amp;#x2019;s license agreement with Harvard University;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;the cost of acquiring, developing and
 manufacturing clinical trial materials and lab supplies;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;facility, depreciation and other
 expenses, which include direct and allocated expenses for rent,
 maintenance of the Company&amp;#x2019;s facilities, insurance and other
 supplies; and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;costs associated with preclinical
 activities and regulatory operations.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Costs for certain development activities, such as clinical trials,
 are recognized based on an evaluation of the progress to completion
 of specific tasks using data such as patient enrollment, clinical
 site activations, or information provided to the Company by its
 vendors on their actual costs incurred. Payments for these
 activities are based on the terms of the individual arrangements,
 which may differ from the pattern of costs incurred, and are
 reflected in the financial statements as prepaid or accrued
 research and development.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_FA318319-25AA-4717-A8C2-B7E1EE8D4DA4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The accompanying interim condensed consolidated financial
 statements are unaudited. These unaudited financial statements have
 been prepared in accordance with the rules and regulations of the
 United States Securities and Exchange Commission
 (&amp;#x201C;SEC&amp;#x201D;) for interim financial information. Accordingly,
 they do not include all of the information and footnotes required
 by United States generally accepted accounting principles
 (&amp;#x201C;GAAP&amp;#x201D;) for complete financial statements. These
 unaudited interim consolidated financial statements should be read
 in conjunction with the audited consolidated financial statements
 and the accompanying notes for the year ended December&amp;#xA0;31,
 2013 contained in the Company&amp;#x2019;s annual report on Form 10-K
 filed with the SEC on March&amp;#xA0;6, 2014 pursuant to Rule 424(b)(4)
 under the Securities Act of 1933, as amended. The unaudited interim
 condensed consolidated financial statements have been prepared on
 the same basis as the annual consolidated financial statements and,
 in the opinion of management, reflect all adjustments (consisting
 of normal recurring adjustments) necessary to state fairly the
 Company&amp;#x2019;s financial position as of June&amp;#xA0;30, 2014, and
 the results of operations and comprehensive loss for the three and
 six months ended June&amp;#xA0;30, 2014 and 2013 and cash flows for the
 six months ended June 30, 2014 and 2013. Interim operating results
 for the three and six months ended June&amp;#xA0;30, 2014 are not
 necessarily indicative of the results that may be expected for
 future interim periods or for the fiscal year ending
 December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The December&amp;#xA0;31, 2013 condensed consolidated balance sheet
 included herein was derived from audited consolidated financial
 statements, but does not include all disclosures including notes
 required by GAAP for complete financial statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_9648FB0B-7B4D-41CC-848E-E374912A286D_3001_5">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="pure" decimals="4" id="id_5950807_44E99F0C-1E8C-483C-B4B7-C699ABBA5BCD_1_8">0.0171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="shares" decimals="INF" id="id_5950807_9A53C01F-94D5-4AAD-AD78-7C1E0B16A492_5001_4">256152</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_DEAE0C9E-CA05-477D-BD02-482CCF5DF9A8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Concentrations of Credit Risk and Off-Balance Sheet
 Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Financial instruments that potentially subject the Company to
 concentrations of credit risk are primarily cash, cash equivalents
 and restricted cash. The Company maintains its cash and cash
 equivalent balances in the form of cash and money market accounts
 with financial institutions that management believes are
 creditworthy. The Company&amp;#x2019;s investment policy includes
 guidelines on the quality of the institutions and financial
 instruments and defines allowable investments that the Company
 believes minimize its exposure to concentration of credit risk. The
 Company has no financial instruments with off-balance-sheet risk of
 loss.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_EF4FE939-3150-46A6-9A1D-B090D9D42928_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;(3) Significant Agreements and Contracts&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In August&amp;#xA0;2006, the Company entered into a license agreement
 for certain intellectual property with Harvard University (the
 &amp;#x201C;University&amp;#x201D;). Under the license agreement, the Company
 has paid the University an aggregate of $3.8 million in upfront
 license fees and development milestone payments, and has issued
 31,379 shares of common stock to the University.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company is obligated to make certain payments totaling up to
 approximately $15.1&amp;#xA0;million upon achievement of certain
 development and regulatory milestones and royalties on net sales of
 products covered by the agreement. In January&amp;#xA0;2007 and April
 2010, the Company and the University amended the license agreement
 to include certain additional intellectual property. The Company
 paid an additional $25,000 to the University with each amendment.
 In February 2011, the license agreement was further amended to
 include additional intellectual property in the license granted by
 the University without the payment of any additional consideration.
 The Company also paid a $2.0 million milestone fee in October 2013
 in connection with the dosing of the first patient in the
 Company&amp;#x2019;s Phase 3 clinical trial of eravacycline for the
 treatment of cIAI.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Government Grant and Contracts&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;BARDA Contract for Eravacycline&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company has received funding for its lead product candidate,
 eravacycline, under an award from BARDA. In January 2012, BARDA
 awarded a five-year contract that provides for up to a total of
 $67.0 million in funding for the development, manufacturing and
 clinical evaluation of eravacycline for the treatment of disease
 caused by bacterial biothreat pathogens.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 In connection with the BARDA Contract, in February 2012, the
 Company entered into a five-year cost-plus-fixed-fee subcontract
 with CUBRC under which it may receive funding of up to
 approximately $39.8 million, reflecting the portion of the BARDA
 funding that may be paid to the Company for its activities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Although the BARDA Contract and the Company&amp;#x2019;s subcontract
 with CUBRC under the BARDA Contract, have five-year terms, BARDA is
 entitled to terminate the project for convenience at any time, and
 is not obligated to provide continued funding beyond current-year
 amounts from Congressionally approved annual appropriations. To the
 extent that BARDA ceases to provide funding of the program to
 CUBRC, CUBRC has the right to cease providing funding to the
 Company. Committed funding from CUBRC under the Company&amp;#x2019;s
 BARDA subcontract is $22.0 million through January&amp;#xA0;31, 2016,
 the current contract end date, as a result of the exercise of
 several options by BARDA under the BARDA Contract. Total funds of
 $14.3 million had been received by the Company through
 June&amp;#xA0;30, 2014 under this contract.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;NIAID Grant and Contract for TP-271&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company has received funding for its preclinical compound
 TP-271 under two awards from NIAID for the development,
 manufacturing and clinical evaluation of TP-271 for respiratory
 diseases caused by biothreat and antibiotic-resistant public health
 pathogens, as well as bacterial pathogens associated with
 community-acquired bacterial pneumonia:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;the NIAID Grant awarded in July 2011
 that provides up to a total of approximately $2.8 million over five
 years; and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;the NIAID Contract awarded in
 September 2011 that provides up to a total of approximately $35.8
 million in funding over five years.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In connection with the NIAID Grant, in November 2011, CUBRC awarded
 the Company a 55-month, no-fee subaward of approximately $980,000,
 reflecting the portion of the NIAID Grant funding that may be paid
 to the Company for its activities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In connection with the NIAID Contract, in October 2011, the Company
 entered into a five-year cost-plus-fixed-fee subcontract with CUBRC
 under which the Company may receive funding of up to approximately
 $13.3 million, reflecting the portion of the NIAID Contract funding
 that may be paid to the Company for its activities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Although the NIAID Contract, the NIAID Grant and the
 Company&amp;#x2019;s subcontract with CUBRC under the NIAID Contract
 have terms of five years, and the Company&amp;#x2019;s subaward under
 the NIAID Grant has a term of 55 months, NIAID is entitled to
 terminate the project for convenience at any time, and is not
 obligated to provide continued funding beyond September&amp;#xA0;30,
 2016. To the extent NIAID ceases to provide funding of the programs
 to CUBRC, CUBRC has the right to cease providing funding to the
 Company. As of June&amp;#xA0;30, 2014, committed funding from CUBRC
 under the Company&amp;#x2019;s subcontract with respect to the NIAID
 Contract is $7.6 million through the current contract end date
 which has been extended to September&amp;#xA0;30, 2016, of which $5.8
 million had been received through June&amp;#xA0;30, 2014. Committed
 funding from CUBRC under the Company&amp;#x2019;s subaward with respect
 to the NIAID Grant is $0.8 million through the current contract end
 date which has been extended to May&amp;#xA0;30, 2016, of which $0.6
 million had been received through June&amp;#xA0;30, 2014.&lt;/p&gt;
 
 
 &lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_8E59680B-8B19-4961-AEA9-D985AC7F9C86_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Operating segments are defined as components of an enterprise about
 which separate discrete information is available for evaluation by
 the chief operating decision maker, or decision-making group, in
 deciding how to allocate resources and in assessing performance.
 The Company views its operations and manages its business in one
 operating segment, which is the business of developing and
 commercializing its proprietary chemistry technology to create
 novel antibiotics for serious and life-threatening
 multidrug-resistant infections.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_D1C80A49-1854-4AC4-8C79-F801BB9F6BA2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;(2) Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The accompanying interim condensed consolidated financial
 statements are unaudited. These unaudited financial statements have
 been prepared in accordance with the rules and regulations of the
 United States Securities and Exchange Commission
 (&amp;#x201C;SEC&amp;#x201D;) for interim financial information. Accordingly,
 they do not include all of the information and footnotes required
 by United States generally accepted accounting principles
 (&amp;#x201C;GAAP&amp;#x201D;) for complete financial statements. These
 unaudited interim consolidated financial statements should be read
 in conjunction with the audited consolidated financial statements
 and the accompanying notes for the year ended December&amp;#xA0;31,
 2013 contained in the Company&amp;#x2019;s annual report on Form 10-K
 filed with the SEC on March&amp;#xA0;6, 2014 pursuant to Rule 424(b)(4)
 under the Securities Act of 1933, as amended. The unaudited interim
 condensed consolidated financial statements have been prepared on
 the same basis as the annual consolidated financial statements and,
 in the opinion of management, reflect all adjustments (consisting
 of normal recurring adjustments) necessary to state fairly the
 Company&amp;#x2019;s financial position as of June&amp;#xA0;30, 2014, and
 the results of operations and comprehensive loss for the three and
 six months ended June&amp;#xA0;30, 2014 and 2013 and cash flows for the
 six months ended June 30, 2014 and 2013. Interim operating results
 for the three and six months ended June&amp;#xA0;30, 2014 are not
 necessarily indicative of the results that may be expected for
 future interim periods or for the fiscal year ending
 December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The December&amp;#xA0;31, 2013 condensed consolidated balance sheet
 included herein was derived from audited consolidated financial
 statements, but does not include all disclosures including notes
 required by GAAP for complete financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Operating segments are defined as components of an enterprise about
 which separate discrete information is available for evaluation by
 the chief operating decision maker, or decision-making group, in
 deciding how to allocate resources and in assessing performance.
 The Company views its operations and manages its business in one
 operating segment, which is the business of developing and
 commercializing its proprietary chemistry technology to create
 novel antibiotics for serious and life-threatening
 multidrug-resistant infections.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of financial statements in conformity with GAAP
 requires management to make estimates and assumptions that affect
 the reported amounts of assets, liabilities, revenue and expenses
 and related disclosures. On an ongoing basis, the Company&amp;#x2019;s
 management evaluates its estimates, including estimates related to
 clinical trial accruals, stock-based compensation expense, contract
 and grant revenues, and expenses. The Company bases its estimates
 on historical experience and other market-specific or other
 relevant assumptions that it believes to be reasonable under the
 circumstances. Actual results may differ from those estimates or
 assumptions.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Concentrations of Credit Risk and Off-Balance Sheet
 Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Financial instruments that potentially subject the Company to
 concentrations of credit risk are primarily cash, cash equivalents
 and restricted cash. The Company maintains its cash and cash
 equivalent balances in the form of cash and money market accounts
 with financial institutions that management believes are
 creditworthy. The Company&amp;#x2019;s investment policy includes
 guidelines on the quality of the institutions and financial
 instruments and defines allowable investments that the Company
 believes minimize its exposure to concentration of credit risk. The
 Company has no financial instruments with off-balance-sheet risk of
 loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The condensed consolidated financial statements include the
 accounts of the Company and its wholly owned subsidiary, Tetraphase
 Securities Corporation, a Massachusetts Securities Corporation. All
 significant intercompany balances and transactions have been
 eliminated in consolidation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company considers all highly liquid investments with maturities
 of three months or less from the date of purchase to be cash
 equivalents. Cash and cash equivalents at June&amp;#xA0;30, 2014 and
 December&amp;#xA0;31, 2013 consisted of cash and money market
 funds.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s financial instruments consist principally of
 cash and cash equivalents, accounts receivable, accounts payable,
 accrued liabilities, and term loan payable. Fair value measurements
 are classified and disclosed in one of the following three
 categories:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="1%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="92%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Quoted prices in active markets for identical
 assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Inputs other than Level&amp;#xA0;1 that are
 observable, either directly or indirectly, such as quoted prices
 for similar assets or liabilities; quoted prices in markets that
 are not active; or other inputs that are observable or can be
 corroborated by observable market data for substantially the full
 term of the assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&amp;#x2014;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;Unobservable inputs that are supported by little
 or no market activity and that are significant to the fair value of
 the assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Financial instruments measured at fair value as of June&amp;#xA0;30,
 2014 and December&amp;#xA0;31, 2013 are classified below based on the
 three fair value hierarchy tiers described above (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;Fair Value Measurements at&lt;br /&gt;
 Reporting Date Using&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Balance&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;June&amp;#xA0;30, 2014&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,255&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,255&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Money market funds, included in cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72,116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2013&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,704&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,704&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Money market funds, included in cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100,008&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;100,008&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company measures cash equivalents at fair value on a recurring
 basis. The fair value of cash equivalents is determined based on
 &amp;#x201C;Level 1&amp;#x201D; inputs, which consist of quoted prices in
 active markets for identical assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of the Company&amp;#x2019;s term loan payable is
 determined using current applicable rates for similar instruments
 as of the balance sheet date. The Company&amp;#x2019;s term loan payable
 is a Level 3 liability within the fair value hierarchy. The fair
 value of the Company&amp;#x2019;s term loan payable at June&amp;#xA0;30,
 2014, computed pursuant to a discounted cash flow technique using
 the effective interest rate under the loan, is $8.1 million. The
 effective interest rate considers the fair value of the warrant
 issued in connection with the loan, loan issuance costs and the
 deferred charge.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of the preferred stock warrant liability as of
 March&amp;#xA0;25, 2013 was determined based on
 &amp;#x201C;Level&amp;#xA0;3&amp;#x201D; inputs utilizing the Black-Scholes
 option pricing model (Note 6).&amp;#xA0;On March&amp;#xA0;25, 2013, upon
 completion of the Company&amp;#x2019;s initial public offering
 (&amp;#x201C;IPO&amp;#x201D;), the warrants to purchase preferred stock
 converted into warrants to purchase common stock and the Company
 reclassified the fair value of the warrants as of March&amp;#xA0;25,
 2013 to additional paid-in capital. The following table presents
 activity in the preferred stock warrant liability during the six
 months ended June&amp;#xA0;30, 2013 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="90%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Balance&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Fair value at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Value of warrants issued in 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;115&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Decrease in fair value recognized in net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(263&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Reclassification of fair value to additional paid-in capital&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(462&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Fair value at June&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In September 2011, the National Institutes of Health&amp;#x2019;s
 (&amp;#x201C;NIH&amp;#x201D;) National Institute of Allergy and Infectious
 Diseases (&amp;#x201C;NIAID&amp;#x201D;) division awarded a contract of up to
 $35.8 million over a five-year term for the development of TP-271,
 a preclinical compound, for respiratory disease caused by bacterial
 biothreat pathogens (&amp;#x201C;NIAID Contract&amp;#x201D;) (Note 3). The
 Company is collaborating with CUBRC Inc. (&amp;#x201C;CUBRC&amp;#x201D;), an
 independent, not for profit, research corporation that specializes
 in U.S. government-based contracts, on this NIAID Contract and has
 entered into a subcontract with CUBRC that could potentially
 provide funding to the Company of up to approximately $13.3 million
 over the five-year term, including committed funding of
 $7.6&amp;#xA0;million from the initial contract date through
 September&amp;#xA0;30, 2016, of which $5.8 million had been received by
 the Company through June&amp;#xA0;30, 2014. In addition during 2011,
 the Company was a subawardee under a separate grant from the NIAID
 (&amp;#x201C;NIAID Grant&amp;#x201D;) (Note 3).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In January 2012 the Biomedical Advanced Research and Development
 Authority (&amp;#x201C;BARDA&amp;#x201D;), an agency of the U.S. Department
 of Health and Human Services, awarded a contract of up to $67.0
 million for the development of eravacycline as a potential
 countermeasure for the treatment of disease caused by bacterial
 biothreat pathogens (&amp;#x201C;BARDA Contract&amp;#x201D;). The Company is
 also collaborating with CUBRC on the BARDA Contract and has entered
 into a subcontract with CUBRC that could potentially provide
 funding to the Company of up to approximately $39.8 million,
 including committed funding of $22.0 million from the initial
 contract date through January&amp;#xA0;31, 2016, of which $14.3 million
 had been received by the Company through June&amp;#xA0;30, 2014
 (Note&amp;#xA0;3).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Accounts receivable at June&amp;#xA0;30, 2014 and December&amp;#xA0;31,
 2013 represent amounts due from CUBRC under the Company&amp;#x2019;s
 subcontracts under the NIAID Contract and the BARDA Contract and
 under the Company&amp;#x2019;s subaward under the NIAID Grant. The
 Company&amp;#x2019;s practice is to bill the prime contractor, CUBRC,
 amounts for which the Company has been invoiced by third parties in
 the case of contract research or subcontractor costs or for
 internal costs incurred. Expenses directly associated with the
 Company&amp;#x2019;s NIAID and BARDA Contracts and NIAID Grant that have
 been accrued at the end of the reporting period are not billed to
 the prime contractor until third party invoices have been received
 or until internal costs have been paid. There was no unbilled
 accounts receivable balance at June&amp;#xA0;30, 2014. Unbilled
 accounts receivable was $0.8 million at December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment, Net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Property and equipment are stated at cost, less accumulated
 depreciation and amortization. Depreciation and amortization are
 provided using the straight-line method over the estimated useful
 lives of the respective assets, which is generally three to five
 years. Leasehold improvements are amortized over the shorter of the
 lease term or the estimated useful economic lives of the related
 assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 At June&amp;#xA0;30, 2014 and December&amp;#xA0;31, 2013 the Company had
 $199,000 in restricted cash deposits with a bank, of which $159,000
 is collateral for a letter of credit issued to the landlord of the
 Company&amp;#x2019;s leased facility. If the Company defaults on its
 rental obligations, $159,000 will be payable to the lessor of the
 leased facility. In addition, the Company has $40,000 in restricted
 cash to secure the Company&amp;#x2019;s corporate credit card issued
 through the same bank.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s revenue is derived from its subcontracts with
 CUBRC under the BARDA Contract and the NIAID Contract and its
 subaward under the NIAID Grant (Note 3). The Company recognizes
 revenue under these best-efforts, cost-reimbursable and
 cost-plus-fixed-fee subcontracts and subaward as the Company
 performs services under the subcontracts and subaward so long as a
 subcontract and subaward has been executed and the fees for these
 services are fixed or determinable, legally billable and reasonably
 assured of collection. Recognized amounts reflect the
 Company&amp;#x2019;s partial performance under the subcontracts and
 subaward and equal direct and indirect costs incurred plus fixed
 fees, where applicable. The Company does not recognize revenue
 under these arrangements for amounts related to contract periods
 where funding is not yet committed as amounts above committed
 funding thresholds would not be considered fixed or determinable or
 reasonably assured of collection. Revenues and expenses under these
 arrangements are presented gross on the condensed consolidated
 statements of operations and comprehensive loss as the Company has
 determined it is the primary obligor under these arrangements
 relative to the research and development services it performs as
 lead technical expert.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenue under the Company&amp;#x2019;s subcontract with respect to the
 BARDA Contract is earned under a cost-reimbursable contract through
 which the Company is reimbursed for direct costs incurred plus
 allowable indirect costs. Billings under the Company&amp;#x2019;s
 subcontract under the BARDA Contract are based on approved
 provisional indirect billing rates that permit recovery of
 allowable fringe benefits, overhead and general and administrative
 expenses. During the three months ended June&amp;#xA0;30, 2014 and
 2013, the Company recognized revenue of $0.8 million and $3.1
 million, respectively, from the Company&amp;#x2019;s subcontract under
 the BARDA Contract. During the six months ended June&amp;#xA0;30, 2014
 and 2013, the Company recognized revenue of $2.6 million and $5.0
 million, respectively, from the Company&amp;#x2019;s subcontract under
 the BARDA Contract.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenue under the Company&amp;#x2019;s subcontract with respect to the
 NIAID Contract is earned under a cost-plus-fixed-fee contract
 through which the Company is reimbursed for direct costs incurred
 plus allowable indirect costs and a fixed-fee earned. Billings
 under the Company&amp;#x2019;s subcontract under the NIAID Contract are
 based on approved provisional indirect billing rates that permit
 recovery of allowable fringe benefits, overhead and general and
 administrative expenses and a fixed fee. During the three months
 ended June&amp;#xA0;30, 2014 and 2013, the Company recognized revenue
 of $0.4 million and $0.5 million, respectively, from the
 Company&amp;#x2019;s subcontract under the NIAID Contract. During the
 six months ended June&amp;#xA0;30, 2014 and 2013, the Company
 recognized revenue of $1.0 million and $1.2 million, respectively,
 from the Company&amp;#x2019;s subcontract under the NIAID Contract.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenue under the Company&amp;#x2019;s subaward with respect to the
 NIAID Grant is earned under a cost-reimbursable contract through
 which the Company is reimbursed for direct costs incurred plus
 allowable indirect costs. Billings under the Company&amp;#x2019;s
 subaward under the NIAID Grant are based on approved provisional
 indirect billing rates that permit recovery of allowable fringe
 benefits and general and administrative expenses. During the three
 months ended June&amp;#xA0;30, 2014 and 2013, the Company recognized
 revenue of $32,000, and $78,000, respectively, from the
 Company&amp;#x2019;s subaward under the NIAID Grant. During the six
 months ended June&amp;#xA0;30, 2014 and 2013, the Company recognized
 revenue of $89,000, and $231,000, respectively, from the
 Company&amp;#x2019;s subaward under the NIAID Grant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Research and development costs are charged to expense as incurred
 and include, but are not limited to:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;personnel-related expenses, including
 salaries, benefits, and stock-based compensation expense;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;expenses incurred under agreements
 with contract research organizations, contract manufacturing
 organizations and consultants that conduct clinical trials and
 preclinical studies;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;payments made under the
 Company&amp;#x2019;s license agreement with Harvard University;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;the cost of acquiring, developing and
 manufacturing clinical trial materials and lab supplies;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;facility, depreciation and other
 expenses, which include direct and allocated expenses for rent,
 maintenance of the Company&amp;#x2019;s facilities, insurance and other
 supplies; and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;costs associated with preclinical
 activities and regulatory operations.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Costs for certain development activities, such as clinical trials,
 are recognized based on an evaluation of the progress to completion
 of specific tasks using data such as patient enrollment, clinical
 site activations, or information provided to the Company by its
 vendors on their actual costs incurred. Payments for these
 activities are based on the terms of the individual arrangements,
 which may differ from the pattern of costs incurred, and are
 reflected in the financial statements as prepaid or accrued
 research and development.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Comprehensive Loss&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Comprehensive loss consists of net income or loss and changes in
 equity during a period from transactions and other events and
 circumstances generated from non-owner sources. The Company&amp;#x2019;s
 net loss equals comprehensive loss for all periods presented.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company uses the liability method of accounting for income
 taxes. Under this method, deferred tax assets and liabilities are
 determined based on the difference between the financial reporting
 and the tax reporting basis of assets and liabilities and are
 measured using the enacted tax rates and laws that are expected to
 be in effect when the differences are expected to reverse. The
 Company provides a valuation allowance against net deferred tax
 assets unless, based upon the available evidence, it is more likely
 than not that the deferred tax assets will be realized. The Company
 has evaluated available evidence and concluded that the Company may
 not realize the benefit of its deferred tax assets; therefore a
 valuation allowance has been established for the full amount of the
 deferred tax assets. The Company&amp;#x2019;s practice is to recognize
 interest and/or penalties related to income tax matters in income
 tax expense.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company applies the provisions of Accounting Standards
 Codification (&amp;#x201C;ASC&amp;#x201D;) 718,&lt;i&gt;&amp;#xA0;Compensation-Stock
 Compensation&lt;/i&gt; to stock-based awards.&amp;#xA0;Under ASC 718, the
 Company determines equity-based compensation at the grant date
 using the Black-Scholes option pricing model to estimate fair
 value. The Company recognizes the value of the award that is
 ultimately expected to vest as an expense on a straight-line basis
 over the requisite service period using the estimated fair market
 value of the stock. Any changes to the estimated forfeiture rates
 are accounted for prospectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements Issued and
 Adopted&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 During the quarter ended&amp;#xA0;June&amp;#xA0;30, 2014, the Financial
 Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;) issued Accounting
 Standards Update (&amp;#x201C;ASU&amp;#x201D;) No.&amp;#xA0;2014-09, Revenue from
 Contracts with Customers (Topic 606), which supersedes all existing
 revenue recognition requirements, including most industry-specific
 guidance. The new standard requires a company to recognize revenue
 when it transfers goods or services to customers in an amount that
 reflects the consideration that the company expects to receive for
 those goods or services. The new standard will be effective for the
 Company on January&amp;#xA0;1, 2017. The Company is currently
 evaluating the potential impact that this update may have on the
 Company&amp;#x2019;s financial position and results of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 During the quarter ended&amp;#xA0;June&amp;#xA0;30, 2014, the FASB issued
 ASU 2014-10, which simplifies financial reporting for development
 stage entities by eliminating requirements specific to development
 stage entities. As a result, entities in a development stage will
 no longer need to present inception-to-date information about
 income statement line items, cash flows, and equity transactions.
 Instead, the new guidance clarifies how these entities should
 tailor existing disclosures to explain the risks and uncertainties
 related to their activities. This update is effective for annual
 periods beginning after December&amp;#xA0;15, 2014, and early
 application is permitted for any annual or interim period for which
 the entity&amp;#x2019;s financial statements have not yet been issued.
 The Company adopted this guidance prior to issuing the financial
 statements in the Form 10-Q for the three and six months ended
 June&amp;#xA0;30, 2014. The adoption of ASU 2014-10 impacted disclosure
 only and did not have any impact on the Company&amp;#x2019;s financial
 position or results of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company considers events or transactions that occur after the
 balance sheet date but prior to the issuance of the financial
 statements to provide additional evidence relative to certain
 estimates or to identify matters that require additional
 disclosure.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Net Loss per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic net loss per share is calculated by dividing the net loss by
 the weighted average number of shares of Common Stock outstanding
 for the period, without consideration for common stock equivalents.
 Diluted net loss per share is computed by dividing the net loss by
 the weighted average number of common share equivalents outstanding
 for the period determined using the treasury-stock method. For
 purposes of this calculation, preferred stock, stock options and
 warrants are considered to be common stock equivalents and are only
 included in the calculation of diluted net loss per share when
 their effect is dilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On February&amp;#xA0;28, 2013, the Company&amp;#x2019;s board of directors
 approved an amendment to the Company&amp;#x2019;s certificate of
 incorporation to effect a 1-for-29 reverse split of its common
 stock. The Company effected this amendment to its certificate of
 incorporation on March&amp;#xA0;5, 2013.&amp;#xA0;Following the
 Company&amp;#x2019;s reverse split, and effective as of the completion
 of the Company&amp;#x2019;s IPO on March&amp;#xA0;25, 2013, all of the
 Company&amp;#x2019;s preferred stock was converted to common stock at a
 1-for-29 ratio. For purposes of calculating net loss per common
 share for the six months ended June&amp;#xA0;30, 2013, the preferred
 stock that converted to common stock was included in the net loss
 per common share calculation on a post-conversion basis as of
 March&amp;#xA0;25, 2013, the effective date of conversion, and the
 corresponding converted shares were included on a pro-rata basis
 for each applicable reporting period. As a result, the
 weighted-average common shares outstanding during the six months
 ended June&amp;#xA0;30, 2013 was 11.3&amp;#xA0;million, as compared to
 20.7&amp;#xA0;million shares outstanding as of June&amp;#xA0;30, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The amounts in the table below were excluded from the calculation
 of diluted weighted-average shares outstanding, prior to the use of
 the treasury stock method, due to their anti-dilutive effect:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 7pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;104,107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,701,914&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,686,892&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_A7690936-957B-4061-B4D1-C70E97F4414B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Prepaid expenses and other current assets at June&amp;#xA0;30, 2014 and
 December&amp;#xA0;31, 2013 consisted of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Prepaid insurance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;269&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Prepaid clinical costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;508&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;462&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Prepaid manufacturing costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;387&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Prepaid rent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;119&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Prepaid dues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;148&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,774&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,002&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="shares" decimals="INF" id="id_5950807_9A53C01F-94D5-4AAD-AD78-7C1E0B16A492_5001_5">119927</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_1DD5F861-CDB1-43F2-9FB2-0FD4657BA188_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Stock-based compensation expense recognized in the Company&amp;#x2019;s
 condensed consolidated statements of operations for stock options
 granted during the periods presented was as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&lt;br /&gt;
 Ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six&amp;#xA0;Months&lt;br /&gt;
 Ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;484&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;152&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,355&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;183&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,066&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;280&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;335&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:UseOfEstimates contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_19149902-6ECE-4CE6-88CC-BB794426D37F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of financial statements in conformity with GAAP
 requires management to make estimates and assumptions that affect
 the reported amounts of assets, liabilities, revenue and expenses
 and related disclosures. On an ongoing basis, the Company&amp;#x2019;s
 management evaluates its estimates, including estimates related to
 clinical trial accruals, stock-based compensation expense, contract
 and grant revenues, and expenses. The Company bases its estimates
 on historical experience and other market-specific or other
 relevant assumptions that it believes to be reasonable under the
 circumstances. Actual results may differ from those estimates or
 assumptions.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_E8A58D21-E01D-43CD-A800-EA4EC610A08C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;(1) Organization and Operations&lt;/b&gt;&lt;/p&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Tetraphase Pharmaceuticals, Inc. (the &amp;#x201C;Company&amp;#x201D;), is a
 clinical-stage biopharmaceutical company that was incorporated in
 Delaware on July&amp;#xA0;7, 2006 and has a principal place of business
 in Watertown, Massachusetts. The Company is using its proprietary
 chemistry technology to create novel antibiotics for serious and
 life-threatening multidrug-resistant infections. The
 Company&amp;#x2019;s lead product candidate, eravacycline, is being
 developed as a broad-spectrum intravenous and oral antibiotic for
 use as a first-line empiric monotherapy for the treatment of
 multidrug-resistant infections, including multidrug-resistant
 Gram-negative infections. The Company is developing eravacycline in
 a Phase 3 global clinical program called IGNITE
 (&lt;b&gt;I&lt;/b&gt;nvestigating &lt;b&gt;G&lt;/b&gt;ram-&lt;b&gt;N&lt;/b&gt;egative &lt;b&gt;I&lt;/b&gt;nfections
 &lt;b&gt;T&lt;/b&gt;reated with &lt;b&gt;E&lt;/b&gt;ravacycline) and is conducting two
 Phase 3 clinical trials - IGNITE 1, a Phase 3 clinical trial
 evaluating the safety and efficacy of eravacycline with intravenous
 administration for the treatment of complicated intra-abdominal
 infections (&amp;#x201C;cIAI&amp;#x201D;), and IGNITE 2, a second Phase 3
 clinical trial of eravacycline for the treatment of complicated
 urinary tract infections (&amp;#x201C;cUTI&amp;#x201D;) with
 intravenous-to-oral switch therapy. IGNITE 2 is a two-part Phase 3
 clinical trial that includes a lead-in portion which is designed to
 inform the selection of an oral dose to be evaluated in the pivotal
 portion of the trial. In July 2014, the Company announced the
 completion of enrollment of IGNITE 1 and in June 2014, announced
 the completion of enrollment of the lead-in portion of IGNITE 2 and
 expects to have data from the lead-in portion of IGNITE 2 in the
 third quarter of 2014, top-line data from IGNITE 1 in early first
 quarter of 2015, and top-line data from the pivotal portion of
 IGNITE 2 in mid-2015. The Company is also pursuing the discovery
 and development of additional antibiotics that target unmet medical
 needs, including multidrug-resistant Gram-negative bacteria.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company is devoting substantially all of its efforts to product
 research and development, initial market development, and raising
 capital. The Company is subject to a number of risks similar to
 those of other life science companies in a similar stage of
 development, including dependence on key individuals, competition
 from other companies, the need for development of commercially
 viable products, and the need to obtain additional financing to
 fund the development of its product candidates. The Company is also
 subject to a number of risks similar to other companies in the
 industry, including rapid technological change, regulatory approval
 of products, uncertainty of market acceptance of products,
 competition, the need to obtain additional financing, compliance
 with government regulations, protection of proprietary technology,
 dependence on third parties, product liability, and dependence on
 key individuals.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has incurred annual net operating losses in every year
 since its inception. As of June&amp;#xA0;30, 2014, the Company had
 incurred losses since inception of $151.7 million. The Company has
 not generated any product revenues related to its primary business
 purpose and has financed its operations primarily through public
 offerings and private placements of its equity securities, debt
 financings and funding from the United States government. The
 Company has not completed development of any product candidate and
 has devoted substantially all of its financial resources and
 efforts to research and development, including preclinical and
 clinical development. The Company expects to continue to incur
 significant expenses and increasing operating losses for at least
 the next several years, and expects to require additional financial
 resources to advance its product candidates to either commercial
 stage or liquidity events.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 There can be no assurance that the Company will be able to obtain
 additional debt or equity financing or generate revenues from
 collaborative partners, on terms acceptable to the Company, on a
 timely basis or at all. The failure of the Company to obtain
 sufficient funds on acceptable terms when needed could have a
 material adverse effect on the Company&amp;#x2019;s business, results of
 operations and financial condition.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_8BD84818-4FB6-4580-9F84-F674E5F6B7DE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Net Loss per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic net loss per share is calculated by dividing the net loss by
 the weighted average number of shares of Common Stock outstanding
 for the period, without consideration for common stock equivalents.
 Diluted net loss per share is computed by dividing the net loss by
 the weighted average number of common share equivalents outstanding
 for the period determined using the treasury-stock method. For
 purposes of this calculation, preferred stock, stock options and
 warrants are considered to be common stock equivalents and are only
 included in the calculation of diluted net loss per share when
 their effect is dilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On February&amp;#xA0;28, 2013, the Company&amp;#x2019;s board of directors
 approved an amendment to the Company&amp;#x2019;s certificate of
 incorporation to effect a 1-for-29 reverse split of its common
 stock. The Company effected this amendment to its certificate of
 incorporation on March&amp;#xA0;5, 2013.&amp;#xA0;Following the
 Company&amp;#x2019;s reverse split, and effective as of the completion
 of the Company&amp;#x2019;s IPO on March&amp;#xA0;25, 2013, all of the
 Company&amp;#x2019;s preferred stock was converted to common stock at a
 1-for-29 ratio. For purposes of calculating net loss per common
 share for the six months ended June&amp;#xA0;30, 2013, the preferred
 stock that converted to common stock was included in the net loss
 per common share calculation on a post-conversion basis as of
 March&amp;#xA0;25, 2013, the effective date of conversion, and the
 corresponding converted shares were included on a pro-rata basis
 for each applicable reporting period. As a result, the
 weighted-average common shares outstanding during the six months
 ended June&amp;#xA0;30, 2013 was 11.3&amp;#xA0;million, as compared to
 20.7&amp;#xA0;million shares outstanding as of June&amp;#xA0;30, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The amounts in the table below were excluded from the calculation
 of diluted weighted-average shares outstanding, prior to the use of
 the treasury stock method, due to their anti-dilutive effect:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 7pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52,605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;104,107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,701,914&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,686,892&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_A1944C5B-36E3-4CAA-B476-FCEA873E820D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During the three and six months ended June&amp;#xA0;30, 2014 and 2013,
 respectively, the assumptions used in the Black-Scholes pricing
 model for new employee grants were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="3" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Volatility factor&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;53.41-53.83%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;58.41-58.73%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.31-6.11&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.97-6.11&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rates&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.73-2.05%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;0.91-1.30%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="3" align="center"&gt;&lt;b&gt;Six&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;June
 30,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Volatility factor&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;53.41-53.96%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;54.50-58.73%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.31-6.11&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.82-6.11&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rates&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.71-2.13%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0.91-1.30%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 
 
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_3A45ED18-701E-43C9-80A3-AB447628E1C3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company uses the liability method of accounting for income
 taxes. Under this method, deferred tax assets and liabilities are
 determined based on the difference between the financial reporting
 and the tax reporting basis of assets and liabilities and are
 measured using the enacted tax rates and laws that are expected to
 be in effect when the differences are expected to reverse. The
 Company provides a valuation allowance against net deferred tax
 assets unless, based upon the available evidence, it is more likely
 than not that the deferred tax assets will be realized. The Company
 has evaluated available evidence and concluded that the Company may
 not realize the benefit of its deferred tax assets; therefore a
 valuation allowance has been established for the full amount of the
 deferred tax assets. The Company&amp;#x2019;s practice is to recognize
 interest and/or penalties related to income tax matters in income
 tax expense.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="pure" decimals="4" id="id_5950807_44E99F0C-1E8C-483C-B4B7-C699ABBA5BCD_1_9">0.0213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:Revenues contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_3_0">3732000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_12">784000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_3_14">-31986000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_3_9">24000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_25">3126000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_3_7">9000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_3_5">-31403000</us-gaap:OperatingIncomeLoss>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_8">-1000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:InterestPaid contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_33">438000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_11">-363000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_3_10">-583000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_3_11">-31986000</us-gaap:NetIncomeLoss>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_18">56000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_3_3">6118000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_4">132000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_28">-2759000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_15">-92000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_7">2205000</us-gaap:ShareBasedCompensation>
  <us-gaap:OperatingCostsAndExpenses contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_3_4">35135000</us-gaap:OperatingCostsAndExpenses>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_3">53000</us-gaap:DepreciationAndAmortization>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_29">-27341000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_19">-56000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_14">669000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_3_8">616000</us-gaap:InterestExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_13">4843000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:AccretionExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_5">70000</us-gaap:AccretionExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_3_2">29017000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_1CF1BD08-987D-49BA-A636-C93317BCC4BA_1_27">367000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3CF4E30D-3DA0-4B50-8DAE-30D89729646F_3_2">2205000</us-gaap:AllocatedShareBasedCompensationExpense>
  <ttph:CashAndCashEquivalentsMaturityPeriodDescription contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_4827CAA7-9A2F-4606-9ED9-5C00FBD30C82_1_0">Three  months or less</ttph:CashAndCashEquivalentsMaturityPeriodDescription>
  <ttph:EstimatedForfeitureRate contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" unitRef="pure" decimals="3" id="id_5950807_66601670-9986-4198-976C-29D8E0326020_1_0">0.050</ttph:EstimatedForfeitureRate>
  <ttph:InitialPublicOfferingsCompletionDate contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_A35114D7-933E-4424-AD50-4F499AB23DBE_1_0">2013-03-25</ttph:InitialPublicOfferingsCompletionDate>
  <ttph:PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_05494D45-F86C-460A-AEC2-4AA09B689505_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;(4) Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Prepaid expenses and other current assets at June&amp;#xA0;30, 2014 and
 December&amp;#xA0;31, 2013 consisted of the following (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Prepaid insurance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;269&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Prepaid clinical costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;508&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;462&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Prepaid manufacturing costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;387&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Prepaid rent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;119&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;89&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Prepaid dues&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;148&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,774&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,002&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ttph:PrepaidExpenseAndOtherCurrentAssetsDisclosureTextBlock>
  <ttph:ScheduleOfPreferredStockWarrantLiabilityTableTextBlock contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0" id="id_5950807_A237137B-D323-49E4-993B-CB8B01A2CED3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table presents activity in the preferred stock
 warrant liability during the six months ended June&amp;#xA0;30, 2013
 (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="90%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Balance&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Fair value at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Value of warrants issued in 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;115&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Decrease in fair value recognized in net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(263&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Reclassification of fair value to additional paid-in capital&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(462&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Fair value at June&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ttph:ScheduleOfPreferredStockWarrantLiabilityTableTextBlock>
  <us-gaap:RevenueFromGrants contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_926233x1038577_926744x1070296" unitRef="iso4217_USD" decimals="0" id="id_5950807_1396B07E-D0B0-4FE6-B41D-D74713C5E576_1003_0">89000</us-gaap:RevenueFromGrants>
  <us-gaap:ProceedsFromGrantors contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_926233x1038577_926744x1070296" unitRef="iso4217_USD" decimals="-5" id="id_5950807_5B2F3895-5292-4ECE-AEE8-00FE4FEA926B_1001_3">600000</us-gaap:ProceedsFromGrantors>
  <us-gaap:RevenueFromGrants contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_926233x1038577_926744x1112837" unitRef="iso4217_USD" decimals="-5" id="id_5950807_9E6F3154-FD7F-4E0F-87A6-7DE8762C5F98_1003_0">1000000</us-gaap:RevenueFromGrants>
  <us-gaap:ProceedsFromGrantors contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_926233x1126999_926744x1070296" unitRef="iso4217_USD" decimals="-5" id="id_5950807_5B2F3895-5292-4ECE-AEE8-00FE4FEA926B_2001_1">5800000</us-gaap:ProceedsFromGrantors>
  <us-gaap:RevenueFromGrants contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_926233x1126999_926744x1112837" unitRef="iso4217_USD" decimals="-5" id="id_5950807_F1922899-5E4E-4DEF-A288-CA6496B3A03C_1003_0">2600000</us-gaap:RevenueFromGrants>
  <us-gaap:ProceedsFromGrantors contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_926233x1126999_926744x1112837" unitRef="iso4217_USD" decimals="-5" id="id_5950807_2730A159-51F0-43F5-BD69-D11F640F32CA_1002_3">14300000</us-gaap:ProceedsFromGrantors>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_926437x923140" id="id_5950807_44E99F0C-1E8C-483C-B4B7-C699ABBA5BCD_1001_6">P6Y1M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_926437x923140" id="id_5950807_58CF6D3C-57DE-418F-8C72-E90E3514E555_1001_1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_926437x932953" id="id_5950807_44E99F0C-1E8C-483C-B4B7-C699ABBA5BCD_2001_5">P5Y3M22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_926437x932953" id="id_5950807_58CF6D3C-57DE-418F-8C72-E90E3514E555_2001_0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <ttph:ContractMaturityDate contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_926744x1112837" id="id_5950807_2730A159-51F0-43F5-BD69-D11F640F32CA_3002_4">2016-01-31</ttph:ContractMaturityDate>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_927015x925832" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3CF4E30D-3DA0-4B50-8DAE-30D89729646F_1003_1">1355000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_927015x928963" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3CF4E30D-3DA0-4B50-8DAE-30D89729646F_2003_0">850000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_928305x924898" unitRef="shares" decimals="INF" id="id_5950807_A11CADE4-655C-4EDB-86DB-EED9A07BA430_1001_1">3701914</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_928305x929614" unitRef="shares" decimals="INF" id="id_5950807_A11CADE4-655C-4EDB-86DB-EED9A07BA430_2001_0">52605</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE719251--1410-Q0005_STD_181_20140630_0_929038x999506" id="id_5950807_06DEE920-F3E2-4116-A801-6EF99B484469_1004_2">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="eol_PE719251--1410-Q0005_STD_28_20130228_0_926396x1117504_931308x1008215" unitRef="iso4217_USD" decimals="-5" id="id_5950807_0B861D5C-A061-4E68-A3D9-EA95BD44E5C7_2001_3">3000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <ttph:DebtInstrumentRedemptionRate contextRef="eol_PE719251--1410-Q0005_STD_28_20130228_0_926396x1117504_931308x1008215" unitRef="pure" decimals="INF" id="id_5950807_4EEC327D-1763-4C67-B92B-7829DBD0EB3D_3001_3">0.0290</ttph:DebtInstrumentRedemptionRate>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE719251--1410-Q0005_STD_28_20130228_0_926396x1117504_931308x1008215_932980x930400" unitRef="shares" decimals="INF" id="id_5950807_4EEC327D-1763-4C67-B92B-7829DBD0EB3D_4001_9">233372</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <ttph:ClassOfWarrantOrRightTermExercisePeriod contextRef="eol_PE719251--1410-Q0005_STD_28_20130228_0_926396x1117504_931308x1008215_932980x930400" id="id_5950807_4EEC327D-1763-4C67-B92B-7829DBD0EB3D_4001_10">P10Y</ttph:ClassOfWarrantOrRightTermExercisePeriod>
  <ttph:ThresholdOfSharesOutstandingForDeterminingAvailabilityOfGrants contextRef="eol_PE719251--1410-Q0005_STD_28_20130228_0_929038x999506" unitRef="shares" decimals="INF" id="id_5950807_EAABAE2B-E268-4B76-85A6-F608444BE228_2001_2">3000000</ttph:ThresholdOfSharesOutstandingForDeterminingAvailabilityOfGrants>
  <ttph:PercentageThresholdOfOutstandingStockForDeterminingAvailabilityOfGrants contextRef="eol_PE719251--1410-Q0005_STD_28_20130228_0_929038x999506" unitRef="pure" decimals="2" id="id_5950807_EAABAE2B-E268-4B76-85A6-F608444BE228_2001_3">0.04</ttph:PercentageThresholdOfOutstandingStockForDeterminingAvailabilityOfGrants>
  <ttph:ContractTerm contextRef="eol_PE719251--1410-Q0005_STD_29_20120229_0_926233x1126999_926744x1112837" id="id_5950807_8B90D036-89F3-4D59-81E6-81CB3AAAA16F_1001_1">P5Y</ttph:ContractTerm>
  <ttph:ContractTerm contextRef="eol_PE719251--1410-Q0005_STD_30_20111130_0_926233x1038577_926744x1070296" id="id_5950807_026A8A24-5BD6-46F7-BD8C-FD156AFBEBF8_1001_1">P55M</ttph:ContractTerm>
  <us-gaap:PaymentsForRoyalties contextRef="eol_PE719251--1410-Q0005_STD_30_20100430_0_926233x925806" unitRef="iso4217_USD" decimals="0" id="id_5950807_032D322A-023A-4E36-A8B3-E5BA37776979_2002_0">25000</us-gaap:PaymentsForRoyalties>
  <ttph:ContractTerm contextRef="eol_PE719251--1410-Q0005_STD_30_20110930_0_926233x1126999_926744x1070296" id="id_5950807_5B7AE169-0800-4774-BB28-1A9689719020_1001_3">P5Y</ttph:ContractTerm>
  <ttph:AwardedContractForResearchAndDevelopment contextRef="eol_PE719251--1410-Q0005_STD_30_20110930_0_926437x923140_926744x1070296" unitRef="iso4217_USD" decimals="-5" id="id_5950807_5B7AE169-0800-4774-BB28-1A9689719020_2001_0">35800000</ttph:AwardedContractForResearchAndDevelopment>
  <ttph:ContractTerm contextRef="eol_PE719251--1410-Q0005_STD_30_20110930_0_926744x1070296" id="id_5950807_5B7AE169-0800-4774-BB28-1A9689719020_3001_1">P5Y</ttph:ContractTerm>
  <us-gaap:PaymentsForRoyalties contextRef="eol_PE719251--1410-Q0005_STD_31_20070131_0_926233x925806" unitRef="iso4217_USD" decimals="0" id="id_5950807_032D322A-023A-4E36-A8B3-E5BA37776979_2001_0">25000</us-gaap:PaymentsForRoyalties>
  <ttph:AwardedContractForResearchAndDevelopment contextRef="eol_PE719251--1410-Q0005_STD_31_20110731_0_926437x923140_926744x1070296" unitRef="iso4217_USD" decimals="-5" id="id_5950807_54CD5745-EE81-4C6F-B338-F9772D3B9D0D_1001_0">2800000</ttph:AwardedContractForResearchAndDevelopment>
  <ttph:ContractTerm contextRef="eol_PE719251--1410-Q0005_STD_31_20110731_0_926744x1070296" id="id_5950807_54CD5745-EE81-4C6F-B338-F9772D3B9D0D_2001_1">P5Y</ttph:ContractTerm>
  <ttph:ContractTerm contextRef="eol_PE719251--1410-Q0005_STD_31_20111031_0_926233x1126999_926744x1070296" id="id_5950807_AD0A8FD9-8B8B-48BD-AD74-83FF74B0E077_1001_1">P5Y</ttph:ContractTerm>
  <ttph:AwardedContractForResearchAndDevelopment contextRef="eol_PE719251--1410-Q0005_STD_31_20120131_0_926437x923140_926744x1112837" unitRef="iso4217_USD" decimals="-5" id="id_5950807_2730A159-51F0-43F5-BD69-D11F640F32CA_2001_0">67000000</ttph:AwardedContractForResearchAndDevelopment>
  <ttph:ContractTerm contextRef="eol_PE719251--1410-Q0005_STD_31_20120131_0_926744x1112837" id="id_5950807_0371A297-4CA6-4B20-A9C0-5AA9C6985EE4_2001_1">P5Y</ttph:ContractTerm>
  <ttph:MilestonePayments contextRef="eol_PE719251--1410-Q0005_STD_31_20131031_0_925123x1035870_926233x925806" unitRef="iso4217_USD" decimals="-5" id="id_5950807_032D322A-023A-4E36-A8B3-E5BA37776979_1003_1">2000000</ttph:MilestonePayments>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE719251--1410-Q0005_STD_31_20140131_0_929038x1056245" unitRef="shares" decimals="INF" id="id_5950807_EAABAE2B-E268-4B76-85A6-F608444BE228_1003_5">1025171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE719251--1410-Q0005_STD_31_20100531_0_929038x999506" unitRef="shares" decimals="INF" id="id_5950807_06DEE920-F3E2-4116-A801-6EF99B484469_1002_1">1853288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE719251--1410-Q0005_STD_31_20110531_0_926396x978559" id="id_5950807_BE05A941-C7F6-45E8-A8E8-54EC3E01BD21_1001_5">2014-11-01</us-gaap:DebtInstrumentMaturityDate>
  <ttph:DebtInstrumentRedemptionRate contextRef="eol_PE719251--1410-Q0005_STD_31_20110531_0_926396x978559" unitRef="pure" decimals="INF" id="id_5950807_BE05A941-C7F6-45E8-A8E8-54EC3E01BD21_1001_4">0.0275</ttph:DebtInstrumentRedemptionRate>
  <ttph:LoanAgreementNumberOfTranches contextRef="eol_PE719251--1410-Q0005_STD_31_20110531_0_926396x978559" unitRef="Tranches" decimals="INF" id="id_5950807_BE05A941-C7F6-45E8-A8E8-54EC3E01BD21_1001_1">2</ttph:LoanAgreementNumberOfTranches>
  <ttph:DebtInstrumentNumberOfInstallment contextRef="eol_PE719251--1410-Q0005_STD_31_20110531_0_926396x978559" unitRef="Installment" decimals="INF" id="id_5950807_BE05A941-C7F6-45E8-A8E8-54EC3E01BD21_1001_6">33</ttph:DebtInstrumentNumberOfInstallment>
  <ttph:ClassOfWarrantOrRightTermExercisePeriod contextRef="eol_PE719251--1410-Q0005_STD_31_20110531_0_926396x978559_932980x930400" id="id_5950807_BE05A941-C7F6-45E8-A8E8-54EC3E01BD21_2001_7">P10Y</ttph:ClassOfWarrantOrRightTermExercisePeriod>
  <ttph:UpfrontAndMilestonePayments contextRef="eol_PE719251--1410-Q0005_STD_31_20060831_0_926233x925806" unitRef="iso4217_USD" decimals="-5" id="id_5950807_C0F2E3A8-182E-4C63-A7D1-6F6D56F3DA73_1001_0">3800000</ttph:UpfrontAndMilestonePayments>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE719251--1410-Q0005_STD_31_20121231_0_926396x1061900_931308x1104289" id="id_5950807_4EEC327D-1763-4C67-B92B-7829DBD0EB3D_1002_4">2016-03-01</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="eol_PE719251--1410-Q0005_STD_31_20121231_0_926396x1061900_931308x1104289" unitRef="iso4217_USD" decimals="-5" id="id_5950807_0B861D5C-A061-4E68-A3D9-EA95BD44E5C7_1002_2">6200000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <ttph:DebtInstrumentRedemptionRate contextRef="eol_PE719251--1410-Q0005_STD_31_20121231_0_926396x1061900_931308x1104289" unitRef="pure" decimals="INF" id="id_5950807_4EEC327D-1763-4C67-B92B-7829DBD0EB3D_1002_1">0.0290</ttph:DebtInstrumentRedemptionRate>
  <ttph:DebtInstrumentNumberOfInstallment contextRef="eol_PE719251--1410-Q0005_STD_31_20121231_0_926396x1061900_931308x1104289" unitRef="Installment" decimals="INF" id="id_5950807_4EEC327D-1763-4C67-B92B-7829DBD0EB3D_1002_0">33</ttph:DebtInstrumentNumberOfInstallment>
  <ttph:ClassOfWarrantOrRightTermExercisePeriod contextRef="eol_PE719251--1410-Q0005_STD_31_20121231_0_926396x1061900_931308x1104289_932980x930400" id="id_5950807_4EEC327D-1763-4C67-B92B-7829DBD0EB3D_2002_5">P10Y</ttph:ClassOfWarrantOrRightTermExercisePeriod>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE719251--1410-Q0005_STD_31_20121231_0_926396x1117504_931308x1008215" id="id_5950807_4EEC327D-1763-4C67-B92B-7829DBD0EB3D_3002_8">2016-05-01</us-gaap:DebtInstrumentMaturityDate>
  <ttph:DebtInstrumentRedemptionRate contextRef="eol_PE719251--1410-Q0005_STD_31_20121231_0_926396x1117504_931308x1008215" unitRef="pure" decimals="INF" id="id_5950807_4EEC327D-1763-4C67-B92B-7829DBD0EB3D_3002_3">0.0290</ttph:DebtInstrumentRedemptionRate>
  <ttph:DebtInstrumentNumberOfInstallment contextRef="eol_PE719251--1410-Q0005_STD_31_20121231_0_926396x1117504_931308x1008215" unitRef="Installment" decimals="INF" id="id_5950807_4EEC327D-1763-4C67-B92B-7829DBD0EB3D_3002_2">33</ttph:DebtInstrumentNumberOfInstallment>
  <ttph:LoanAgreementNumberOfTranches contextRef="eol_PE719251--1410-Q0005_STD_31_20121231_0_926396x978559" unitRef="Tranches" decimals="INF" id="id_5950807_0B861D5C-A061-4E68-A3D9-EA95BD44E5C7_3002_1">2</ttph:LoanAgreementNumberOfTranches>
  <ttph:DebtInstrumentInterestOnlyPeriod contextRef="eol_PE719251--1410-Q0005_STD_31_20121231_0_926396x978559" id="id_5950807_4EEC327D-1763-4C67-B92B-7829DBD0EB3D_5002_13">P6M</ttph:DebtInstrumentInterestOnlyPeriod>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="eol_PE719251--1410-Q0005_STD_365_20111231_0_926396x978559" unitRef="iso4217_USD" decimals="-5" id="id_5950807_BE05A941-C7F6-45E8-A8E8-54EC3E01BD21_1002_2">8000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE719251--1410-Q0005_STD_365_20131231_0" id="id_5950807_9648FB0B-7B4D-41CC-848E-E374912A286D_1001_2">P7Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="eol_PE719251--1410-Q0005_STD_365_20131231_0" unitRef="pure" decimals="3" id="id_5950807_570C3778-B9DD-40DC-8F0B-8C0CCC3EF3EF_1_0">0.034</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="eol_PE719251--1410-Q0005_STD_365_20131231_0_929038x932097" id="id_5950807_3FE524C2-4F0B-4DD7-869C-AFFD3CCD3198_1001_1">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE719251--1410-Q0005_STD_365_20131231_0_929038x932097" id="id_5950807_3FE524C2-4F0B-4DD7-869C-AFFD3CCD3198_1001_0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="pure" decimals="4" id="id_5950807_A27136AD-A182-45EC-9A39-F399BE273B91_2_2">0.5841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="shares" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_2_13">20575000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="pure" xsi:nil="true" id="id_5950807_A27136AD-A182-45EC-9A39-F399BE273B91_2_10" />
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_2_12">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="pure" decimals="4" id="id_5950807_A27136AD-A182-45EC-9A39-F399BE273B91_2_3">0.5873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="pure" decimals="4" id="id_5950807_A27136AD-A182-45EC-9A39-F399BE273B91_2_8">0.0091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="pure" decimals="4" id="id_5950807_A27136AD-A182-45EC-9A39-F399BE273B91_2_9">0.0130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:Revenues contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_2_0">3722000</us-gaap:Revenues>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_2_14">-5426000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_2_7">2000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_2_5">-4958000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_2_10">-468000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_2_11">-5426000</us-gaap:NetIncomeLoss>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_2_3">1756000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingCostsAndExpenses contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_2_4">8680000</us-gaap:OperatingCostsAndExpenses>
  <us-gaap:InterestExpense contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_2_8">470000</us-gaap:InterestExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_2_2">6924000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3CF4E30D-3DA0-4B50-8DAE-30D89729646F_2_2">280000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:RevenueFromGrants contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0_926233x1038577_926744x1070296" unitRef="iso4217_USD" decimals="0" id="id_5950807_1396B07E-D0B0-4FE6-B41D-D74713C5E576_1002_0">78000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0_926233x1038577_926744x1112837" unitRef="iso4217_USD" decimals="-5" id="id_5950807_9E6F3154-FD7F-4E0F-87A6-7DE8762C5F98_1002_0">500000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0_926233x1126999_926744x1112837" unitRef="iso4217_USD" decimals="-5" id="id_5950807_F1922899-5E4E-4DEF-A288-CA6496B3A03C_1002_0">3100000</us-gaap:RevenueFromGrants>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0_926437x923140" id="id_5950807_A27136AD-A182-45EC-9A39-F399BE273B91_1002_6">P6Y1M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0_926437x932953" id="id_5950807_A27136AD-A182-45EC-9A39-F399BE273B91_2002_5">P5Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0_927015x925832" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3CF4E30D-3DA0-4B50-8DAE-30D89729646F_1002_1">140000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE719251--1410-Q0005_STD_91_20130630_0_927015x928963" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3CF4E30D-3DA0-4B50-8DAE-30D89729646F_2002_0">140000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="pure" decimals="4" id="id_5950807_A27136AD-A182-45EC-9A39-F399BE273B91_1_2">0.5341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="shares" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_1_13">25845000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="pure" xsi:nil="true" id="id_5950807_A27136AD-A182-45EC-9A39-F399BE273B91_1_10" />
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_1_12">-0.71</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="pure" decimals="4" id="id_5950807_A27136AD-A182-45EC-9A39-F399BE273B91_1_3">0.5383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="pure" decimals="4" id="id_5950807_A27136AD-A182-45EC-9A39-F399BE273B91_1_8">0.0173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="pure" decimals="4" id="id_5950807_A27136AD-A182-45EC-9A39-F399BE273B91_1_9">0.0205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:Revenues contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_1_0">1275000</us-gaap:Revenues>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_1_14">-18463000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_1_7">4000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_1_5">-18185000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_1_10">-278000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_1_11">-18463000</us-gaap:NetIncomeLoss>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_1_3">2947000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingCostsAndExpenses contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_1_4">19460000</us-gaap:OperatingCostsAndExpenses>
  <us-gaap:InterestExpense contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_1_8">282000</us-gaap:InterestExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_87DEEF27-184D-4F5B-875B-AFCFEE33D5A9_1_2">16513000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3CF4E30D-3DA0-4B50-8DAE-30D89729646F_1_2">1066000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:RevenueFromGrants contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0_926233x1038577_926744x1070296" unitRef="iso4217_USD" decimals="0" id="id_5950807_1396B07E-D0B0-4FE6-B41D-D74713C5E576_1001_0">32000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0_926233x1038577_926744x1112837" unitRef="iso4217_USD" decimals="-5" id="id_5950807_9E6F3154-FD7F-4E0F-87A6-7DE8762C5F98_1001_0">400000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0_926233x1126999_926744x1112837" unitRef="iso4217_USD" decimals="-5" id="id_5950807_F1922899-5E4E-4DEF-A288-CA6496B3A03C_1001_0">800000</us-gaap:RevenueFromGrants>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0_926437x923140" id="id_5950807_A27136AD-A182-45EC-9A39-F399BE273B91_1001_6">P6Y1M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0_926437x932953" id="id_5950807_A27136AD-A182-45EC-9A39-F399BE273B91_2001_5">P5Y3M22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0_927015x925832" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3CF4E30D-3DA0-4B50-8DAE-30D89729646F_1001_1">582000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE719251--1410-Q0005_STD_91_20140630_0_927015x928963" unitRef="iso4217_USD" decimals="-3" id="id_5950807_3CF4E30D-3DA0-4B50-8DAE-30D89729646F_2001_0">484000</us-gaap:AllocatedShareBasedCompensationExpense>
  <context id="eol_PE719251--1410-Q0005_STD_91_20140630_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_91_20140630_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_91_20140630_0_926437x932953">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_91_20140630_0_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_91_20140630_0_926233x1126999_926744x1112837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_91_20140630_0_926233x1038577_926744x1112837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubawardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_91_20140630_0_926233x1038577_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubawardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_91_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_91_20130630_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_91_20130630_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_91_20130630_0_926437x932953">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_91_20130630_0_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_91_20130630_0_926233x1126999_926744x1112837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_91_20130630_0_926233x1038577_926744x1112837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubawardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_91_20130630_0_926233x1038577_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubawardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_91_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
    </entity>
    <period>
      <startDate>2013-04-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_365_20131231_0_929038x932097">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_365_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_365_20111231_0_926396x978559">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TermLoanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20121231_0_926396x978559">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TermLoanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-12-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20121231_0_926396x1117504_931308x1008215">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TwoThousandTwelveTermLoanBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttph:SecondTrancheMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-12-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20121231_0_926396x1061900_931308x1104289_932980x930400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TwoThousandTwelveTermLoanAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttph:FirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-12-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20121231_0_926396x1061900_931308x1104289">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TwoThousandTwelveTermLoanAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttph:FirstTrancheMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-12-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20060831_0_926233x925806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2006-08-01</startDate>
      <endDate>2006-08-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20110531_0_926396x978559_932980x930400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-05-01</startDate>
      <endDate>2011-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20110531_0_926396x978559">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TermLoanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-05-01</startDate>
      <endDate>2011-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20100531_0_929038x999506">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttph:StockIncentivePlanTwoThousandSixMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-05-01</startDate>
      <endDate>2010-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20140131_0_929038x1056245">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttph:StockIncentivePlanTwoThousandThirteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20131031_0_925123x1035870_926233x925806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">ttph:PhaseThreeClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20120131_0_926744x1112837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20120131_0_926437x923140_926744x1112837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20111031_0_926233x1126999_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20110731_0_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20110731_0_926437x923140_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-07-01</startDate>
      <endDate>2011-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_31_20070131_0_926233x925806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_30_20110930_0_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-09-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_30_20110930_0_926437x923140_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-09-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_30_20110930_0_926233x1126999_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-09-01</startDate>
      <endDate>2011-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_30_20100430_0_926233x925806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-04-01</startDate>
      <endDate>2010-04-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_30_20111130_0_926233x1038577_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubawardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-11-01</startDate>
      <endDate>2011-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_29_20120229_0_926233x1126999_926744x1112837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-02-01</startDate>
      <endDate>2012-02-29</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_28_20130228_0_929038x999506">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttph:StockIncentivePlanTwoThousandSixMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-02-01</startDate>
      <endDate>2013-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_28_20130228_0_926396x1117504_931308x1008215_932980x930400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TwoThousandTwelveTermLoanBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttph:SecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-02-01</startDate>
      <endDate>2013-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_28_20130228_0_926396x1117504_931308x1008215">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TwoThousandTwelveTermLoanBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttph:SecondTrancheMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-02-01</startDate>
      <endDate>2013-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20140630_0_929038x999506">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttph:StockIncentivePlanTwoThousandSixMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20140630_0_928305x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20140630_0_928305x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20140630_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20140630_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20140630_0_926744x1112837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20140630_0_926437x932953">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20140630_0_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20140630_0_926233x1126999_926744x1112837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20140630_0_926233x1126999_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20140630_0_926233x1038577_926744x1112837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubawardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20140630_0_926233x1038577_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubawardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20130630_0_928305x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20130630_0_928305x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20130630_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20130630_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20130630_0_926437x932953">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20130630_0_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20130630_0_926233x1126999_926744x1112837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20130630_0_926233x1038577_926744x1112837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubawardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20130630_0_926233x1038577_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubawardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_181_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_1_20140623_0_923791x1190399_933025x1575944">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttph:ClassOfWarrantOrRightIssuedDateTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ttph:SvbFinancialGroupMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-06-23</startDate>
      <endDate>2014-06-23</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_1_20140623_0_923791x1190397_933025x1575944">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttph:ClassOfWarrantOrRightIssuedDateOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ttph:SvbFinancialGroupMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-06-23</startDate>
      <endDate>2014-06-23</endDate>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20131231_0_926801x930315">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20131231_0_926801x927260">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CollateralizedCreditCardSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20131231_0_924211x932359_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20131231_0_924211x932359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20131231_0_924211x926224_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20131231_0_924211x926224">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20121231_0_926396x1117504">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TwoThousandTwelveTermLoanBMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20121231_0_926396x1061900_931308x1104289_932980x930400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TwoThousandTwelveTermLoanAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttph:FirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140630_0_929038x999506">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttph:StockIncentivePlanTwoThousandSixMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140630_0_929038x1056245">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttph:StockIncentivePlanTwoThousandThirteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140630_0_926801x930315">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140630_0_926801x927260">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CollateralizedCreditCardSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140630_0_926233x925806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140630_0_926233x1126999_926744x1112837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140630_0_926233x1126999_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140630_0_926233x1038577_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubawardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140630_0_924211x932359_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140630_0_924211x932359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140630_0_924211x926224_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140630_0_924211x926224">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20110930_0_926233x1126999_926744x1070296_928294x1262318">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttph:SeptemberFirstTwoThousandElevenToSeptemberThirtiethTwoThousandSixteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-09-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20110930_0_926233x1126999_926437x923140_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-09-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20060831_0_929038x999506">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttph:StockIncentivePlanTwoThousandSixMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2006-08-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20060831_0_926233x925806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2006-08-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140623_0_923791x1190399_933025x1575944">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttph:ClassOfWarrantOrRightIssuedDateTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ttph:SvbFinancialGroupMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-23</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140623_0_923791x1190397_933025x1575944">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttph:ClassOfWarrantOrRightIssuedDateOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">ttph:SvbFinancialGroupMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-06-23</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20110531_0_926396x978559_932980x930400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-05-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20110531_0_926396x978559">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TermLoanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-05-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20120229_0_926233x1126999_926437x923140_926744x1112837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-02-29</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20140731_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
    </entity>
    <period>
      <instant>2014-07-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20130228_0_929038x999506">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttph:StockIncentivePlanTwoThousandSixMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-02-28</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20130228_0_929038x1056245">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ttph:StockIncentivePlanTwoThousandThirteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-02-28</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20130228_0_926396x1117504_931308x1008215_932980x930400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TwoThousandTwelveTermLoanBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ttph:SecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-02-28</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20130228_0_926396x1117504">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TwoThousandTwelveTermLoanBMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-02-28</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20130228_0_926396x1061900">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttph:TwoThousandTwelveTermLoanAMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-02-28</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20120131_0_926233x1126999_926744x1112837_928294x1262319">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttph:JanuaryFirstTwoThousandTwelveToAprilThirtiethTwoThousandFifteenMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20120131_0_926233x1126999_926437x923140_926744x1112837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20111130_0_926233x1038577_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubawardMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-11-30</instant>
    </period>
  </context>
  <context id="eol_PE719251--1410-Q0005_STD_0_20111031_0_926233x1126999_926437x923140_926744x1070296">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001373707</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ttph:NationalInstitutesOfHealthNationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ttph:SubcontractMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-10-31</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_Right">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>ttph:Right</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Segment">
    <measure>ttph:Segment</measure>
  </unit>
  <unit id="Tranches">
    <measure>ttph:Tranches</measure>
  </unit>
  <unit id="Installment">
    <measure>ttph:Installment</measure>
  </unit>
</xbrl>